CA2190528C - Primate embryonic stem cells - Google Patents

Primate embryonic stem cells Download PDF

Info

Publication number
CA2190528C
CA2190528C CA2190528A CA2190528A CA2190528C CA 2190528 C CA2190528 C CA 2190528C CA 2190528 A CA2190528 A CA 2190528A CA 2190528 A CA2190528 A CA 2190528A CA 2190528 C CA2190528 C CA 2190528C
Authority
CA
Canada
Prior art keywords
cells
primate
ssea
human
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2190528A
Other languages
French (fr)
Other versions
CA2190528A1 (en
Inventor
James A. Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23484566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2190528(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CA2190528A1 publication Critical patent/CA2190528A1/en
Application granted granted Critical
Publication of CA2190528C publication Critical patent/CA2190528C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/13Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Abstract

A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (-); SSEA-3 (+); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a paricularly advantageous embodiment, the cells of the preparation have normal karyotypes and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.

Description

PRIMATE EMBRYONIC STEM CELLS
Field of the Invention In general, the field of the present invention is stem cell cultures. Specifically, the field of the present invention is primate embryonic stem cell cultures.

Background of the Inventiori In general, stem cells are undifferentiated cells which can give rise to a succession of mature functional cells. For example, a hematopoietic stem cell may give rise to any of the different types of terminally differentiated blood cells. Embryonic stem (ES) cells are derived from the embryo and are pluripotent, thus possessing the capability of developing into any organ or tissue type or, at least potentially, into a complete embryo.
One of the seminal achievements of mammalian embryology of the last decade is the routine insertion of specific genes into the mouse genome through the use of mouse ES cells. This alteration has created a bridge between the in vitro manipulations of molecular biology and an understanding of gene function in the intact animal. Mouse ES cells are undifferentiated, 2 219 u 5 ?8 PCT/US96/00596 pluripotent cells derived in vitro from preimplantation embryos (Evans, et al. Nature 292:154-159, 1981; Martin, Proc. Natl. Acad. Sci. USA 78:7634-7638, 1981) or from fetal germ cells (Matsui, et al., Cell 70:841-847, 1992). Mouse ES cells maintain an undifferentiated state through serial passages when cultured in the presence of fibroblast feeder layers in the presence of Leukemia Inhibitory Factor (LIF) (Williams, et al., Nature 336:684-687, 1988). If LIF
is removed, mouse ES cells differentiate.
Mouse ES cells cultured in non-attaching conditions aggregate and differentiate into simple embryoid bodies, with an outer layer of endoderm and an inner core of primitive ectoderm. If these embryoid bodies are then allowed to attach onto a tissue culture surface, disorganized differentiation occurs of various cell types, including nerves, blood cells, muscle, and cartilage (Martin, 1981, supra;
Doetschman, et al., J. Embryol. Exp. Morph. 87:27-45, 1985). Mouse ES cells injected into syngeneic mice form teratocarcinomas that exhibit disorganized differentiation, often with representatives of all three embryonic germ layers. Mouse ES cells combined into chimeras with normal preimplantation embryos and returned to the uterus participate in normal development (Richard, et al., Cytogenet. Cell Genet.
65:169-171, 1994).
The ability of mouse ES cells to contribute to functional germ cells in chimeras provides a method for introducing site-specific mutations into mouse lines. With appropriate transfection and selection strategies, homologous recombination can be used to derive ES cell lines with planned alterations of specific genes. These genetically altered cells can be used to form chimeras with normal embryos and chimeric animals are recovered. If the ES cells contribute to the germ line in the chimeric animal, then in the next.
generation a mouse line for the planned mutation is established.
Because mouse ES cells have the potential to differentiate into any cell type in the body, mouse ES
cells allow the in vitro study of the mechanisms controlling the differentiation of specific cells or tissues. Although the study of mouse ES cells provides clues to understanding the differentiation of general mammalian tissues, dramatic differences in primate and mouse development of specific lineages limits the usefulness of mouse ES cells as a model of human development. Mouse and primate embryos differ meaningfully in the timing of expression of the embryonic genome, in the formation of an egg cylinder versus an embryonic disc (Kaufman, The Atlas of Mouse Development, London: Academic Press, 1992), in the proposed derivation of some early lineages (O'Rahilly & Muller, Developmental Stages in Human Embryos, Washington: Carnegie Institution of Washington, 1987), and in the structure and function in the extraembryonic membranes and placenta (Mossman, Vertebrate Fetal Membranes, New Brunswick: Rutgers, 1987). Other tissues differ in growth factor requirements for development (e.g. the hematopoietic system(Lapidot et al., Lab An Sci 43:147-149, 1994)), and in adult structure and function (e.g. the central nervous system). Because humans are primates, and development is remarkably similar among primates, primate ES cells lines will provide a faithful model for understanding the differentiation of primate tissues in general and human tissues in particular.
The placenta provides just one example of how primate ES cells will provide an accurate model of human development that cannot be provided by ES cells from other species. The placenta and extraembryonic membranes differ dramatically between mice and humans.
Structurally, the mouse placenta is classified as U
labyrinthine, whereas the human and the rhesus monkey placenta are classified as villous. Chorionic gonadotropin, expressed by the trophoblast, is an essential molecule involved in maternal recognition of pregnancy in all primates, including humans (Hearn, J
Reprod Fertil 76:809-819, 1986; Hearn et al., J Reprod Fert 92:497-509, 1991). Trophoblast secretion of chorionic gonadotropin in primates maintains the corpus luteum of pregnancy and, thus, progesterone secretion. Without progesterone, pregnancy fails.
Yet mouse trophoblast produces no chorionic gonadotropin, and mice use entirely different mechanisms for pregnancy maintenance (Hearn et al., "Normal and abnormal embryo-fetal development in mammals," In: Lamming E, ed. Marshall's Physiology of Reproduction. 4th ed. Edinburgh, New York: Churchill Livingstone, 535-676, 1994). An immortal, euploid, primate ES cell line with the developmental potential to form trophoblast in vitro, will allow the study of the ontogeny and function of genes such as chorionic gonadotropin which are critically important in human pregnancy. Indeed, the differentiation of any tissue for which there are significant differences between mice and primates will be more accurately reflected in vitro by primate ES cells than by mouse ES cells.
The major in vitro models for studying trophoblast function include human choriocarcinoma cells, which are malignant cells that may not faithfully reflect normal trophectoderm; short-term primary cultures of human and non-human primate cytotrophoblast, which in present culture conditions quickly form non-dividing syncytial trophoblast; and in vitro culture of preimplantation non-human primate embryos (Hearn, et al., J. Endocrinol. 119:249-255, 1988; Coutifaris, et al., Ann. NY Acad. Sci. 191-201, 1994). An immortal, euploid, non-human primate embryonic stem (ES) cell line with the developmental ..~ WO 96/22362 2 1 / D528 PCT/US96/00596 potential to form trophectoderm offers significant advantages over present in vitro models of human trophectoderm development and function, as trophoblast-specific genes such as chorionic gonadotropin could be stably altered in the ES cells and then studied during differentiation to trophectoderm.
The cell lines currently available that resembles primate ES cells most closely are human embryonic carcinoma (EC) cells, which are pluripotent, immortal cells derived from teratocarcinomas (Andrews, et al., Lab. Invest. 50(2):147-162, 1984; Andrews, et al., in:
Robertson E., ed. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. Oxford: IRL press, pp.
207-246, 1987). EC cells can be induced to differentiate in culture, and the differentiation is characterized by the loss of specific cell surface markers (SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81) and the appearance of new markers (Andrews, et al., 1987, supra). Human EC cells will form teratocarcinomas with derivatives of multiple embryonic lineages in tumors in nude mice. However, the range of differentiation of these human EC cells is limited compared to the range of differentiation obtained with mouse ES cells, and all EC cell lines derived to date are aneuploid (Andrews, et al., 1987, supra). Similar mouse EC cell lines have been derived from teratocarcinomas, and, in general their developmental potential is much more limited than mouse ES cells (Rossant, et al., Cell Differ. 15:155-161, 1984).
Teratocarcinomas are tumors derived from germ cells, and although germ cells (like ES cells) are theoretically totipotent (i.e. capable of forming all cell types in the body), the more limited developmental potential and the abnormal karyotypes of EC cells are thought to result from selective pressures in the teratocarcinoma tumor environment 2 l , ~ '~- ~ 8 (Rossant & Papaioannou, Cell Differ 15:155-161, 1984).
ES cells, on the other hand, are thought to retain greater developmental potential because they are derived from normal embryonic cells in vitro, without the selective pressures of the teratocarcinoma environment. Nonetheless, mouse EC cells and mouse ES
cells share the same unique combination of cell surface markers (SSEA-1 (+), SSEA-3 (-), SSEA-4 (-), and alkaline phosphatase (+)).
Pluripotent cell lines have also been derived from preimplantation embryos of several domestic and laboratory animals species (Evans, et al., Theriogenoloctv 33(1):125-128, 1990; Evans, et al., Theriocrenolocrv 33 (1) :125-128, 1990; Notarianni, et al., J. Reprod. Fertil. 41(Suppl.):51-56, 1990; Giles, et al., Mol. Reprod. Dev. 36:130-138, 1993; Graves, et al., Mol. Reprod. Dev. 36:424-433, 1993; Sukoyan, et al., Mol. Reprod. Dev. 33:418-431, 1992; Sukoyan, et al., Mol. Reprod. Dev. 36:148-158, 1993; Iannaccone, et al., Dev. Biol. 163:288-292, 1994).
Whether or not these cell lines are true ES cells lines is a subject about which there may be some difference of opinion. True ES cells should: (i) be capable of indefinite proliferation in vitro in an undifferentiated state; (ii) maintain a normal karyotype through prolonged culture; and (iii) maintain the potential to differentiate to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture.
Strong evidence of these required properties have been published only for rodents ES cells including mouse (Evans & Kaufman, Nature 292:154-156, 1981; Martin, Proc Natl Acad Sci USA 78:7634-7638, 1981) hamster (Doetschmanet al. Dev Biol 127:224-227, 1988), and rat (Iannaccone et al. Dev Biol 163:288-292, 1994), and less conclusively for rabbit ES cells (Gileset al. Mol Reprod Dev 36:130-138, 1993; Graves & Moreadith, Mol -=- WO 96/22362 PGT/US96/00596 Reprod Dev 36:424-433, 1993). However, only established ES cell lines from the rat (Iannaccone, et al., 1994, su ra) and the mouse (Bradley, et al., Nature 309:255-256, 1984) have been reported to participate in normal development in chimeras. There are no reports of the derivation of any primate ES
cell line.
Summary of the Invention The present invention is a purified preparation of primate embryonic stem cells. The primate ES cell lines are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. The true primate ES cells lines are therefore pluripotent.
The present invention is also summarized in that primate ES cell lines are negative for the SSEA-1 marker, positive for the SSEA-3 marker, and positive for the SSEA-4 marker. Preferably, the primate ES
cell lines are also positive for the TRA-1-60, and TRA-1-81 markers, as well as positive for the alkaline phosphatase marker.
It is an advantageous feature of the present invention that the primate ES cell lines continue to proliferate in an undifferentiated state after continuous culture for at least one year. In a particularly advantageous embodiment, the cells remain euploid after proliferation in an undifferentiated state.
It is a feature of the primate ES cell lines in accordance with the present invention that the cells can differentiate to trophoblast in vitro and express chorionic gonadotropin.

r 2 u 195 2 ~s The present invention is also a purified preparation of primate embryonic stem cells that has the ability to differentiate into cells derived from mesoderm, endoderm, and ectoderm germ layers after the cells have been injected into an immunocompromised mouse, such as a SCID mouse.
The present invention is also a method of isolating a primate embryonic stem cell line. The method comprises the steps of isolating a primate blastocyst, isolating cells from the inner cellular mass (ICM) of the blastocyst, plating the ICM cells on a fibroblast layer (wherein ICM-derived cell masses are formed) removing an ICM-derived cell mass and dissociating the mass into dissociated cells, replating the dissociated cells on embryonic feeder cells and selecting colonies with compact morphology containing cells with a high nucleus/cytoplasm ratio, and prominent nucleoli. The cells of the selected colonies are then cultured.
It is an object of the present invention to provide a primate embryonic stem cell line.
It is an object of the present invention to provide a primate embryonic stem cell line characterized by the following markers: alkaline phosphatase(+); SSEA-1(-); SSEA-3(+); SSEA-4(+); TRA-1-60(+); and TRA-1-8l(+).
It is an object of the present invention to provide a primate embryonic stem cell line capable of proliferation in an undifferentiated state after continuous culture for at least one year. Preferably, these cells remain euploid.
It is another object of the present invention to provide a primate embryonic stem cell line wherein the cells differentiate into cells derived from mesoderm, endoderm, and ectoderm germ layers when the cells are injected into an immunocompromised mouse.
Other objects, features, and advantages of the 2190r~8 ..~ WO 96/22362 PCTIUS96/00596 present invention will become obvious after study of the specification, drawings, and claims.

Description of the Drawings Fig. 1 is a photomicrograph illustrating normal XY karyotype of rhesus ES cell line R278.5 after 11 months of continuous culture.
Fig. 2 is a set of phase-contrast photomicrographs demonstrating the morphology of undifferentiated rhesus ES (R278.5) cells and of cells differentiated from R278.5 in vitro (bar = 100 ).
Photograph A demonstrates the distinct cell borders, high nucleus to cytoplasm ratio, and prominent nucleoli of undifferentiated rhesus ES cells.
Photographs B-D shows differentiated cells eight days after plating R278.5 cells on gel treated tissue culture plastic (with 103 units/ml added human LIF).
Cells of these three distinct morphologies are consistently present when R278.5 cells are allowed to differentiate at low density without fibroblasts either in the presence or absence of soluble human LIF.
Fig. 3 are photomicrographs demonstrating the expression of cell surface markers on undifferentiated rhesus ES (R278.5) cells (bar = l00 ). Photograph A
shows Alkaline Phosphatase (+); Photograph B shows SSEA-1 (-); Photograph C shows SSEA-3 (+);
Photograph D shows SSEA-4 (+); Photograph E shows TRA-1-60 (+); and Photograph F shows TRA-1-81 (+).
Fig. 4 is a photograph illustrating expression of a-fetoprotein mRNA and a- and 0- chorionic gonadotrophin mRNA expression in rhesus ES cells (R278.5) allowed to differentiate in culture.
Fig. 5 includes six photomicrographs of sections of tumors formed by injection of 0.5 X 106 rhesus. ES
(R278.5) cells into the hindleg muscles of SCID mice and analyzed 15 weeks later. Photograph A shows a low power field demonstrating disorganized differentiation of multiple cell types. A gut-like structure is encircled by smooth muscle(s), and elsewhere foci of cartilage (c) are present (bar = 400 ); Photograph B
shows striated muscle (bar = 40 ); Photograph C shows stratified squamous epithelium with several hair follicles. The labeled hair follicle (f) has a visible hair shaft (bar = 200 ); Photograph D shows stratified layers of neural cells in the pattern of a developing neural tube. An upper "ventricular" layer, containing numerous mitotic figures (arrows), overlies a lower "mantle" layer. (bar = 100 ); Photograph E
shows ciliated columnar epithelium (bar = 40 );
Photograph F shows villi covered with columnar epithelium with interspersed mucus-secreting goblet cells (bar = 200 ).
Fig. 6 includes photographs of an embryoid Body.
This embryoid body was formed from a marmoset ES cell line (Cj62) that had been continuously passaged in vitro for over 6 months. Photograph A (above) shows a section of the anterior 1/3 of the embryonic disc.
Note the primitive ectoderm (E) forms a distinct cell layer from the underlying primitive endoderm (e), with no mixing of the cell layers. Note also that amnion (a) is composed of two distinct layers; the inner layer is continuous with the primitive ectoderm at the margins. Photograph B (below) shows a section in the caudal 1/3 of embryonic disc. Note central groove (arrow) and mixing of primitive ectoderm and endoderm representing early primitive streak formation, indicating the beginning of gastrulation. 400X, toluidine blue stain.

Description of the Invention (1) In General (a) Uses of Primate ES Cells The present invention is a pluripotent, immortal euploid primate ES cell line, as exemplified by the isolation of ES cell lines from two primate species, the common marmoset (Callithrix jacchus) and the rhesus monkey (Macaca mulatta). Primate embryonic stem cells are useful for:
(i) Generatincr transgenic non-human primates for models of specific human genetic diseases. Primate embryonic stem cells will allow the generation of primate tissue or animal models for any human genetic disease for which the responsible gene has been cloned. The human genome project will identify an increasing number of genes related to human disease, but will not always provide insights into gene function. Transgenic nonhuman primates will be essential for elucidating mechanisms of disease and for testing new therapies.
(ii) Tissue transplantation. By manipulating culture conditions, primate ES cells, human and non-human, can be induced to differentiate to specific cell types, such as blood cells, neuron cells, or muscle cells. Alternatively, primate ES
cells can be allowed to differentiate in tumors in SCID mice, the tumors can be disassociated, and the specific differentiated cell types of interest can be selected by the usage of lineage specific markers through the use of fluorescent activated cell sorting (FACS) or other sorting method or by direct microdissection of tissues of interest. These differentiated cells could then be transplanted back to the adult animal to treat specific diseases, such as hematopoietic disorders, endocrine deficiencies, degenerative neurological disorders or hair loss.
(b) Selection of Model Species Macaques and marmosets were used as exemplary species for isolation of a primate ES cell line.
Macaques, such as the rhesus monkey, are Old World species that are the major primates used in biomedical.

2 1 - ~ WO 96/22362 il `~ L) ~ PCT/US96/00596 research. They are relatively large (about 7-10 kg).
Males take 4-5 years to mature, and females have single young. Because of the extremely close anatomical and physiological similarities between humans and rhesus monkeys, rhesus monkey true ES cell lines provide a very accurate in vitro model for human differentiation. Rhesus monkey ES cell lines and rhesus monkeys will be particularly useful in the testing of the safety and efficacy of the transplantation of differentiated cell types into whole animals for the treatment of specific diseases or conditions. In addition, the techniques developed for the rhesus ES cell lines model the generation, characterization and manipulation of human ES cell lines.
The common marmoset (Callithrix jacchus) is a New World primate species with reproductive characteristics that make it an excellent choice for ES cell derivation. Marmosets are small (about 350-400 g), have a short gestation period (144 days), reach sexual maturity in about 18 months, and routinely have twins or triplets. Unlike in macaques, it is possible to routinely synchronize ovarian cycles in the marmoset with prostaglandin analogs, making collection of age-matched embryos from multiple females possible, and allowing efficient embryo transfer to synchronized recipients with 700-80% of embryos transferred resulting in pregnancies. Because of these reproductive characteristics that allow for the routine efficient transfer of multiple embryos, marmosets provide an excellent primate species in which to generate transgenic models for human diseases.
There are approximately 200 primate species in the world. The most fundamental division that divides higher primates is between Old World and New world species. The evolutionary distance between the rhesus monkey and the common marmoset is far greater than the evolutionary distance between humans and rhesus monkeys. Because it is here demonstrated that it is possible to isolate ES cell lines from a representative species of both the Old World and New World group using similar conditions, the techniques described below may be used successfully in deriving ES cell lines in other higher primates as well. Given the close evolutionary distance between rhesus macaques and humans, and the fact that feeder-dependent human EC cell lines can be grown in conditions similar to those that support primate ES
cell lines, the same growth conditions will allow the isolation and growth of human ES cells. In addition, human ES cell lines will be permanent cell lines that will also be distinguished from all other permanent human cell lines by their normal karyotype and the expression of the same combination of cell surface markers (alkaline phosphotase, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81) that characterize other primate ES
cell lines. A normal karyotype and the expression of this combination of cell surface markers will be defining properties of true human ES cell lines, regardless of the method used for their isolation and regardless of their tissue of origin.
No other primate (human or non-human) ES cell line is known to exist. The only published permanent, euploid, embryo-derived cell lines that have been convincingly demonstrated to differentiate into derivatives of all three germ layers have been derived from rodents (the mouse, rat, and hamster), and possibly from rabbit. The published reports of embryo-derived cell lines from domestic species have failed to convincingly demonstrate differentiation of derivatives of all three embryonic germ layers or have not been permanent cell lines. Research groups in Britain and Singapore are informally reported, later ~ ~
WO 96/22362 2 1~ ~ ~ ~ ~, ~ J . (/ _ ~ PGT/US96/00596 than the work described here, to have attempted to derive human ES cell lines from surplus in vitro fertilization-produced human embryos, although they have not yet reported success in demonstrating pluripotency of their cells and have failed to isolate permanent cell lines. In the only published report on attempts to isolate human ES cells, conditions were used (LIF in the absence of fibroblast feeder layers) that the results below will indicate will not result in primate ES cells which can remain in an undifferentiated state. It is not surprising, then that the cells grown out of human ICMs failed to continue to proliferate after 1 or 2 subcultures, Bongso et al. Hum. Reprod. 9:2100-2117 (1994).

(2) Embryonic Stem Cell Isolation A preferable medium for isolation of embryonic stem cells is "ES medium." ES medium consists of 800 Dulbecco's modified Eagle's medium (DMEM; no pyruvate, high glucose formulation, Gibco BRL), with 20% fetal bovine serum (FBS; Hyclone), 0.1 mM ,6-mercaptoethanol (Sigma), 1% non-essential amino acid stock (Gibco BRL). Preferably, fetal bovine serum batches are compared by testing clonal plating efficiency of a low passage mouse ES cell line (ES,t3), a cell line developed just for the purpose of this test. FBS
batches must be compared because it has been found that batches vary dramatically in their ability to support embryonic cell growth, but any other method of assaying the competence of FBS batches for support of embryonic cells will work as an alternative.
Primate ES cells are isolated on a confluent layer of murine embryonic fibroblast in the presence of ES cell medium. Embryonic fibroblasts are preferably obtained from 12 day old fetuses from outbred CF1 mice (SASCO), but other strains may be used as an alternative. Tissue culture dishes are ,.. WO 96/22362 ~ ~ ~ ~ ~ 28 PCT/US96/00596 preferably treated with 0.1% gelatin (type I; Sigma).
For rhesus monkey embryos, adult female rhesus monkeys (greater than four years old) demonstrating normal ovarian cycles are observed daily for evidence of menstrual bleeding (day 1 of cycle = the day of onset of inenses). Blood samples are drawn daily during the follicular phase starting from day 8 of the menstrual cycle, and serum concentrations of luteinizing hormone are determined by radioimmunoassay. The female is paired with a male rhesus monkey of proven fertility from day 9 of the menstrual cycle until 48 hours after the luteinizing hormone surge; ovulation is taken as the day following the luteinizing hormone surge. Expanded blastocysts are collected by non-surgical uterine flushing at six days after ovulation. This procedure routinely results in the recovery of an average 0.4 to 0.6 viable embryos per rhesus monkey per month, Seshagiri et al. Am J Primatol 29:81-91, 1993.
For marmoset embryos, adult female marmosets (greater than two years of age) demonstrating regular ovarian cycles are maintained in family groups, with a fertile male and up to five progeny. Ovarian cycles are controlled by intramuscular injection of 0.75 g of the prostaglandin PGF2a analog cloprostenol (Estrumate, Mobay Corp, Shawnee, KS) during the middle to late luteal phase. Blood samples are drawn on day 0 (immediately before cloprostenol injection), and on days 3, 7, 9, 11, and 13. Plasma progesterone concentrations are determined by ELISA. The day of ovulation is taken as the day preceding a plasma progesterone concentration of 10 ng/ml or more. At eight days after ovulation, expanded blastocysts are recovered by a non-surgical uterine flush procedure, Thomson et al. "Non-surgical uterine stage preimplantation embryo collection from the common marmoset," J Med Primatol, 23:333-336 (1994). This ? ~ / 9 (l~ , .., F; ;_. ?~
-L.
~
procedure results in the average production of 1.0 viable embryos per marmoset per month.
The zona pellucida is removed from blastocysts by brief exposure to pronase (Sigma). For immunosurgery, blastocysts are exposed to a 1:50 dilution of rabbit anti-marmoset spleen cell antiserum (for marmoset blastocysts) or a 1:50 dilution of rabbit anti-rhesus monkey (for rhesus monkey blastocysts) in DMEM for 30 minutes, then washed for 5 minutes three times in DMEM, then exposed to a 1:5 dilution of Guinea pig complement (Gibco) for 3 minutes.
After two further washes in DMEM, lysed trophectoderm cells are removed from the intact inner cell mass (ICM) by gentle pipetting, and the ICM
plated on mouse inactivated (3000 rads gamma irradiation) embryonic fibroblasts.
After 7-21 days, ICM-derived masses are removed from endoderm outgrowths with a micropipette with direct observation under a stereo microscope, exposed to 0.0501 Trypsin-EDTA (Gibco) supplemented with 11i chicken serum for 3-5 minutes and gently dissociated by gentle pipetting through a flame polished micropipette.
Dissociated cells are replated on embryonic feeder layers in fresh ES medium, and observed for colony formation. Colonies demonstrating ES-like morphology are individually selected, and split again as described above. The ES-like morphology is defined as compact colonies having a high nucleus to cytoplasm ratio and prominent nucleoli. Resulting ES cells are then routinely split by brief trypsinization or exposure to Dulbecco's Phosphate Buffered Saline (without calcium or magnesium and with 2 mM EDTA) every 1-2 weeks as the cultures become dense. Early passage cells are also frozen and stored in liquid nitrogen.
Cell lines may be karyotyped with a standard G-_ banding technique (such as by the Cytogenetics Laboratory of the University of Wisconsin State Hygiene Laboratory, which provides routine karyotyping services) and compared to published karyotypes for the primate species.
Isolation of ES cell lines from other primate species would follow a similar procedure, except that the rate of development to blastocyst can vary by a few days between species, and the rate of development of the cultured ICMs will vary between species. For example, six days after ovulation, rhesus monkey embryos are at the expanded blastocyst stage, whereas marmoset embryos don't reach the same stage until 7-8 days after ovulation. The Rhesus ES cell lines were obtained by splitting the ICM-derived cells for the first time at 7-16 days after immunosurgery; whereas the marmoset ES cells were derived with the initial split at 7-10 days after immunosurgery. Because other primates also vary in their developmental rate, the timing of embryo collection, and the timing of the initial ICM split will vary between primate species, but the same techniques and culture conditions will allow ES cell isolation.
Because ethical considerations in the U.S. do not allow the recovery of human in vivo fertilized preimplantation embryos from the uterus, human ES
cells that are derived from preimplantation embryos will be derived from in vitro fertilized (IVF) embryos. Experiments on unused (spare) human IVF-produced embryos are allowed in many countries, such as Singapore and the United Kingdom, if the embryos are less than 14 days old. Only high quality embryos are suitable for ES isolation. Present defined culture conditions for culturing the one cell human embryo to the expanded blastocyst are suboptimal but practicable, Bongso et al., Hum Reprod 4:706-713, 1989. Co-culturing of human embryos with human ~ ~
19 UJ%
oviductal cells results in the production of high blastocyst quality. IVF-derived expanded human blastocysts grown in cellular co-culture, or in improved defined medium, will allow the isolation of human ES cells with the same procedures described above for nonhuman primates.

(3) Definincr Characteristics of Primate ES Cells Primate embryonic stem cells share features with the primate ICM and with pluripotent human embryonal carcinoma cells. Putative primate ES cells may therefore be characterized by morphology and by the expression of cell surface markers characteristic of human EC cells. Additionally, putative primate ES
cells may be characterized by developmental potential, karyotype and immortality.
(a) Morphology The colony morphology of primate embryonic stem cell lines is similar to, but distinct from, mouse embryonic stem cells. Both mouse and primate ES cells have the characteristic features of undifferentiated stem cells, with high nuclear/cytoplasmic ratios, prominent nucleoli, and compact colony formation. The colonies of primate ES cells are flatter than mouse ES
cell colonies and individual primate ES cells can be easily distinguished. In Fig. 2, reference character A indicates a phase contrast photomicrograph of cell line R278.5 demonstrating the characteristic primate ES cell morphology.
(b) Cell Surface Markers A primate ES cell line of the present invention is distinct from mouse ES cell lines by the presence or absence of the cell surface markers described below.
One set of glycolipid cell surface markers is known as the Stage-specific embryonic antigens 1 through 4. These antigens can be identified using ,.. , WO 96/22362 217 0528 PCTIUS96/00596 antibodies for SSEA 1, SSEA-3 and SSEA-4 which are available from the Developmental Studies Hybridoma Bank of the National Institute of Child Health and Human Development. The cell surface markers referred to as TRA-1-60 and TRA-1-81 designate antibodies from hybridomas developed by Peter Andrews of the University of Sheffield and are described in Andrews et al., "Cell lines from human germ cell tumors," In:
Robertson E, ed. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. Oxford: IRL Press, 207-246, 1987. The antibodies were localized with a biotinylated secondary antibody and then an avidin/biotinylated horseradish peroxidase complex (Vectastain ABC System, Vector Laboratories).
Alternatively, it should also be understood that other antibodies for these same cell surface markers can be generated. NTERA-2 cl. Dl, a pluripotent human EC
cell line (gift of Peter Andrews), may be used as a negative control for SSEA-1, and as a positive control for SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. This cell line was chosen for positive control only because it has been extensively studied and reported in the literature, but other human EC cell lines may be used as well.
Mouse ES cells (ESj13) are used as a positive control for SSEA-1, and for a negative control for SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. Other routine negative controls include omission of the primary or secondary antibody and substitution of a primary antibody with an unrelated specificity.
Alkaline phosphatase may be detected following fixation of cells with 4% para-formaldehyde using "Vector Red" (Vector Laboratories) as a substrate, as described by the manufacturer (Vector Laboratories).
The precipitate formed by this substrate is red when viewed with a rhodamine filter system, providing substantial amplification over light microscopy.

WO 96/22362 2 19~ j~~ PCT/Us96/00596 Table 1 diagrams a comparison of mouse ES cells, primate ES cells, and human EC cells. The only cells reported to express the combination of markers SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 other than primate ES
cells are human EC cells. The globo-series glycolipids SSEA-3 and SSEA-4 are consistently present on human EC cells, and are of diagnostic value in distinguishing human EC cell tumors from human yolk sac carcinomas, choriocarcinomas, and other lineages which lack these markers, Wenk et al., Int J Cancer 58:108-115, 1994. A recent survey found SSEA-3 and SSEA-4 to be present on all of over 40 human EC cell lines examined, Wenk et al. TRA-1-60 and TRA-1-81 antigens have been studied extensively on a particular pluripotent human EC cell line, NTERA-2 CL. Dl, Andrews et al, supra. Differentiation of NTERA-2 CL.
D1 cells in vitro results in the loss of SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 expression and the increased expression of the lacto-series glycolipid SSEA-l, Andrews et al, supra. This contrasts with undifferentiated mouse ES cells, which express SSEA-1, and neither SSEA-3 nor SSEA-4. Although the function of these antigens are unknown, their shared expression by R278.5 cells and human EC cells suggests a close embryological similarity. Alkaline phosphatase will also be present on all primate ES cells. A successful primate ES cell culture of the present invention will correlate with the cell surface markers found in-the rhesus macaque and marmoset cell lines described in Table 1.
As disclosed below in Table 1, the rhesus macaque and marmoset cell lines are identical to human EC cell lines for the 5 described markers. Therefore, a successful primate ES cell culture will also mimic human EC cells. However, there are other ways to discriminate ES cells from EC cells. For example, the primate ES cell line has a normal karyotype and the human EC cell line is aneuploid.
In Fig. 3, the photographs labelled A through F
demonstrate the characteristic staining of these markers on a rhesus monkey ES cell line designated R278.5.

Table 1 Mouse C. jacchus M. mulatta Human EC
ES ES ES (NTERA-2 cl.Dl) SSEA-1 + - - -SSEA-3 - + + +
SSEA-4 - + + +
Tra-1-60 - + + +
Tra-1-81 - + + +
(c) Developmental Potential Primate ES cells of the present invention are pluripotent. By "pluripotent" we mean that the cell has the ability to develop into any cell derived from the three main germ cell layers or an embryo itself.
When injected into SCID mice, a successful primate ES
cell line will differentiate into cells derived from all three embryonic germ layers including: bone, cartilage, smooth muscle, striated muscle, and hematopoietic cells (mesoderm); liver, primitive gut and respiratory epithelium (endoderm); neurons, glial cells, hair follicles, and tooth buds (ectoderm).
This experiment can be accomplished by injecting approximately 0.5-1.0 X 106 primate ES cells into the rear leg muscles of 8-12 week old male SCID mice.
The resulting tumors can be fixed in 4%
paraformaldehyde and examined histologically after paraffin embedding at 8-16 weeks of development. In Fig. 4, photomicrographs designated A-F are of sections of tumors formed by injection of rhesus ES
cells into the hind leg muscles of SCID mice and analyzed 15 weeks later demonstrating cartilage, smooth muscle, and striated muscle (mesoderm);
stratified squamous epithelium with hair follicles, neural tube with ventricular, intermediate, and mantle layers (ectoderm) ; ciliated columnar epithelium and villi lined by absorptive enterocytes and mucus-secreting goblet cells (endoderm).
A successful nonhuman primate ES cell line will have the ability to participate in normal development when combined in chimeras with normal preimplantation embryos. Chimeras between preimplantation nonhuman primate embryos and nonhuman primate ES cells can be formed by routine methods in several ways. (i) injection chimeras: 10-15 nonhuman primate ES cells can be microinjected into the cavity of an expanded nonhuman primate blastocyst; (ii) aggregation chimeras: nonhuman primate morulae can be co-cultured on a lawn of nonhuman primate ES cells and allowed to aggregate; and (iii) tetraploid chimeras:
10-15 nonhuman primate ES cells can be aggregated with tetraploid nonhuman primate morulae obtained by electrofusion of 2-cell embryos, or incubation of morulae in the cytoskeletal inhibitor cholchicine.
The chimeras can be returned to the uterus of a female nonhuman primate and allowed to develop to term, and the ES cells will contribute to normal differentiated tissues derived from all three embryonic germ layers and to germ cells. Because nonhuman primate ES can be genetically manipulated prior to chimera formation by standard techniques, chimera formation followed by embryo transfer can lead to the production of transgenic nonhuman primates.
(d) Karvotylpe Successful primate ES cell lines have normal karyotypes. Both XX and XY cells lines will be derived. The normal karyotypes in primate ES cell lines will be in contrast to the abnormal karyotype found in human embryonal carcinoma (EC), which are derived from spontaneously arising human germ cell -^- WO 96/22362 214 `y 528 PCTIUS96/00596 tumors (teratocarcinomas). Human embryonal carcinoma cells have a limited ability to differentiate into multiple cell types and represent the closest existing cell lines to primate ES cells. Although tumor-derived human embryonal carcinoma cell lines have some properties in common with embryonic stem cell lines, all human embryonal carcinoma cell lines derived to date are aneuploid. Thus, primate ES cell lines and human EC cell lines can be distinguished by the normal karyotypes found in primate ES cell lines and the abnormal karyotypes found in human EC lines.
By "normal karyotype" it is meant that all chromosomes normally characteristic of the species are present and have not been noticeably altered.
Because of the abnormal karyotypes of human embryonal carcinoma cells, it is not clear how accurately their differentiation reflects normal differentiation. The range of embryonic and extra-embryonic differentiation observed with primate ES
cells will typically exceed that observed in any human embryonal carcinoma cell line, and the normal karyotypes of the primate ES cells suggests that this differentiation accurately recapitulates normal differentiation.
(e) Immortality Immortal cells are capable of continuous indefinite replication in vitro. Continued proliferation for longer than one year of culture is a sufficient evidence for immortality, as primary cell cultures without this property fail to continuously divide for this length of time (Freshney, Culture of animal cells. New York: Wiley-Liss, 1994). Primate ES cells will continue to proliferate in vitro with the culture conditions described above for longer than one year, and will maintain the developmental potential to contribute all three embryonic germ layers. This developmental 2i~0 :r 3~8 potential can be demonstrated by the injection of ES
cells that have been cultured for a prolonged period (over a year) into SCID mice and then histologically examining the resulting tumors. Although karyotypic changes can occur randomly with prolonged culture, some primate ES cells will maintain a normal karyotype for longer than a year of continuous culture.
(f) Culture Conditions Growth factor requirements to prevent differentiation are different for the primate ES cell line of the present invention than the requirements for mouse ES cell lines. In the absence of fibroblast feeder layers, Leukemia inhibitory factor (LIF) is necessary and sufficient to prevent differentiation of mouse ES cells and to allow their continuous passage. Large concentrations of cloned LIF fail to prevent differentiation of primate ES
cell lines in the absence of fibroblast feeder layers. In this regard, primate ES stem cells are again more similar to human EC cells than to mouse ES
cells, as the growth of feeder-dependent human EC
cells lines is not supported by LIF in the absence of fibroblasts.
(g) Differentiation to Extra Embryonic Tissues When grown on embryonic fibroblasts and allowed to grow for two weeks after achieving confluence (i.e., continuously covering the culture surface), primate ES cells of the present invention spontaneously differentiate and will produce chorionic gonadotropin, indicating trophoblast differentiation (a component of the placenta) and produce a-fetoprotein, indicating endoderm differentiation. Chorionic gonadotropin activity can be assayed in the medium conditioned by differentiated cells by Leydig cell bioassay, Seshagiri & Hearn, Hum Reprod 8:279-287, 1992. For mRNA analysis, RNA can be prepared by guanidine isothiocyanate-phenol/chloroform extraction (1) from approximately 0.2 X 106 differentiated cells and from 0.2 X 106 undifferentiated cells. The relative levels of the mRNA for a-fetoprotein and the a- and 0-subunit of chorionic gonadotropin relative to glyceraldehyde-3-phosphate dehydrogenase can be determined by semi-quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).
The PCR primers for glyceraldehyde 3-phosphate dehydrogenase (G3PDH), obtained from Clontech (Palo Alto, CA), are based on the human cDNA sequence, and do not amplify mouse G3PDH mRNA under our conditions.
Primers for the a-fetoprotein mRNA are based on the human sequence and flank the 7th intron (5' primer =
(5') GCTGGATTGTCTGCAGGATGGGGAA (SEQ ID NO: 1); 3' primer = (5') TCCCCTGAAGAP,AATTGGTTAAAAT (SEQ ID NO:
2)). They amplify a cDNA of 216 nucleotides.
Primers for the 0-subunit of chorionic gonadotropin flank the second intron (5' primer =(5') ggatc CACCGTCAACACCACCATCTGTGC (SEQ ID NO: 3); 3' primer =
(5') ggatc CACAGGTCAAAGGGTGGTCCTTGGG (SEQ ID NO: 4)) (nucleotides added to the hCGb sequence to facilitate sub-cloning are shown in lower case italics). They amplify a cDNA of 262 base pairs. The primers for the CGa subunit can be based on sequences of the first and fourth exon of the rhesus gene (5' primer =
(5') gggaattc GCAGTTACTGAGAACTCACAAG (SEQ ID NO: 5);
3' primer = (5') gggaattc GAAGCATGTCAAAGTGGTATGG (SEQ
ID NO: 6)) and amplify a cDNA of 556 base pairs. The identity of the a-fetoprotein, CGa and CGO cDNAs can be verified by subcloning and sequencing.
For Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), 1 to 5 l of total R278.5 RNA can be reverse transcribed as described Golos et al.
Endocrinoloav 133(4):1744-1752, 1993, and one to 20 l of reverse transcription reaction was then 2 1~~ ~?8 subjected to the polymerase chain reaction in a mixture containing 1-12.5 pmol of each G3PDH primer, 10-25 pmol of each mRNA specific primer, 0.25 mM
dNTPs (Pharmacia, Piscataway, NJ), 1X AmpliTaq buffer (final reaction concentrations = 10 mM Tris, pH 8.3, 50 mM KC1, 1.5 mM MgC12, 0.001% (w/v) gelatin) 2.5 Ci of deoxycytidine 5'a[32P]triphosphate (DuPont, Boston, MA), 10% glycerol and 1.25 U of AmpliTaq (Perkin-Elmer, Oak Brook, IL) in a total volume of 50 l. The number of amplification rounds which produced linear increases in target cDNAs and the relation between input RNA and amount of PCR product is empirically determined as by Golos et al. Samples were fractionated in 3% Nusieve (FMC, Rockland, ME) agarose gels (1X TBE running buffer) and DNA bands of interest were cut out, melted at 65 C in 0.5 ml TE, and radioactivity determined by liquid scintillation counting. The ratio of counts per minute in a specific PCR product relative to cpm of G3PDH PCR
product is used to estimate the relative levels of a mRNAs among differentiated and undifferentiated cells.
The ability to differentiate into trophectoderm in vitro and the ability of these differentiated cells to produce chorionic gonadotropin distinguishes the primate ES cell line of the present invention from all other published ES cell lines.

Examples (1) Animals and Embryos As described above, we have developed a technique for non-surgical, uterine-stage embryo recovery from the rhesus macaque and the common marmoset.
To supply rhesus embryos to interested investigators, The Wisconsin Regional Primate Research Center (WRPRC) provides a preimplantation WO 96/22362 PCr/US96/00596 embryo recovery service for the rhesus monkey, using the non-surgical flush procedure described above.
During 1994, 151 uterine flushes were attempted from rhesus monkeys, yielding 80 viable embryos (0.53 embryos per flush attempt).
By synchronizing the reproductive cycles of several marmosets, significant numbers of in vivo produced, age-matched, preimplantation primate embryos were studied in controlled experiments for the first time. Using marmosets from the self-sustaining colony (250 animals) of the Wisconsin Regional Primate Research Center (WRPRC), we recovered 54 viable morulae or blastocysts, 7 unfertilized oocytes or degenerate embryos, and 5 empty zonae pellucidae in a total of 54 flush attempts (1.0 viable embryo-flush attempt). Marmosets have a 28 day ovarian cycle, and because this is a non-surgical procedure, females can be flushed on consecutive months, dramatically increasing the embryo yield compared to surgical techniques which require months of rest between collections.
(2) Rhesus Macaque Embryonic Stem Cells Using the techniques described above, we have derived three independent embryonic stem cell lines from two rhesus monkey blastocysts (R278.5, R366, and R367). One of these, R278.5, remains undifferentiated and continues to proliferate after continuous culture for over one year. R278.5 cells have also been frozen and successfully thawed with the recovery of viable cells.
The morphology and cell surface markers of R278.5 cells are indistinguishable from human EC
cells, and differ significantly from mouse ES cells.
R278.5 cells have a high nucleus/cytoplasm ratio and prominent nucleoli, but rather than forming compact, piled-up colonies with indistinct cell borders similar to mouse ES cells, R278.5 cells form flatter U J
colonies with individual, distinct cells (Fig 2 A).
R278.5 cells express the SSEA-3, SSEA-4, TRA-1-60, and TRA-81 antigens (Fig 3 and Table 1), none of which are expressed by mouse ES cells. The only cells known to express the combination of markers SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 other than primate ES cells are human EC cells. The globo-series glycolipids SSEA-3 and SSEA-4 are consistently present on human EC cells, and are of diagnostic value in distinguishing human EC cell tumors from yolk sac carcinomas, choriocarcinomas and other stem cells derived from human germ cell tumors which lack these markers, Wenk et al, Int J Cancer 58:108-115, 1994. A recent survey found SSEA-3 and SSEA-4 to be present on all of over 40 human EC cell lines examined (Wenk et al.).
TRA-1-60 and TRA-1-81 antigens have been studied extensively on a particular pluripotent human EC cell line, NTERA-2 CL. Di (Andrews et al.).
Differentiation of NTERA-2 CL. Dl cells in vitro results in the loss of SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 expression and the increased expression of the lacto-series glycolipid SSEA-1. Undifferentiated mouse ES cells, on the other hand, express SSEA-1, and not SSEA-3, SSEA-4, TRA-1-60 or TRA-1-81 (Wenk et al.). Although the function of these antigens is unknown, their expression by R278.5 cells suggests a close embryological similarity between primate ES
cells and human EC cells, and fundamental differences between primate ES cells and mouse ES cells.
R278.5 cells also express alkaline phosphatase.
The expression of alkaline phosphatase is shared by both primate and mouse ES cells, and relatively few embryonic cells express this enzyme. Positive cells include the ICM and primitive ectoderm (which are the most similar embryonic cells in the intact embryo to ES cells), germ cells, (which are totipotent), and a very limited number of neural precursors, Kaufman MH.
The atlas of mouse development. London: Academic Press, 1992. Cells not expressing this enzyme will not be primate ES cells.
Although cloned human LIF was present in the medium at cell line derivation and for initial passages, R278.5 cells grown on mouse embryonic fibroblasts without exogenous LIF remain undifferentiated and continued to proliferate.
R278.5 cells plated on gelatin-treated tissue culture plates without fibroblasts differentiated to multiple cell types or failed to attach and died, regardless of the presence or absence of exogenously added human LIF (Fig 2). Up to 104units/ ml human LIF fails to prevent differentiation. In addition, added LIF
fails to increase the cloning efficiency or proliferation rate of R278.5 cells on fibroblasts.
Since the derivation of the R278.5 cell line, we have derived two additional rhesus ES cell lines (R366 and R367) on embryonic fibroblasts without any exogenously added LIF at initial derivation. R366 and R367 cells, like R278.5 cells, continue to proliferate on embryonic fibroblasts without exogenously added LIF and differentiate in the absence of fibroblasts, regardless of the presence of added LIF. RT-PCR performed on mRNA from spontaneously differentiated R278.5 cells revealed a-fetoprotein mRNA (Fig 4). a-fetoprotein is a specific marker for endoderm, and is expressed by both extra-embryonic (yolk sac) and embryonic (fetal liver and intestines) endoderm-derived tissues.
Epithelial cells resembling extraembryonic endoderm are present in cells differentiated in vitro from R278.5 cells (Fig. 2). Bioactive CG (3.89 mI
units/ml) was present in culture medium collected from differentiated cells, but not in medium collected from undifferentiated cells (less than 0.03 WO 96/22362 2 19 J~`8 PCT/US96/00596 mI units/ml), indicating the differentiation of trophoblast, a trophectoderm derivative. The relative level of the CGa mRNA increased 23.9-fold after differentiation (Fig. 4).
All SCID mice injected with R278.5 cells in either intra-muscular or intra-testicular sites formed tumors, and tumors in both sites demonstrated a similar range of differentiation. The oldest tumors examined (15 weeks) had the most advanced differentiation, and all had abundant, unambiguous derivatives of all three embryonic germ layers, including gut and respiratory epithelium (endoderm);
bone, cartilage, smooth muscle, striated muscle (mesoderm); ganglia, glia, neural precursors, and stratified squamous epithelium (ectoderm), and other unidentified cell types (Fig. 5). In addition to individual cell types, there was organized development of some structures which require complex interactions between different cell types. Such structures included gut lined by villi with both absorptive enterocytes and mucus-secreting goblet cells, and sometimes encircled by layers of smooth muscle in the same orientation as muscularis mucosae (circular) and muscularis (outer longitudinal layer and inner circular layer); neural tubes with ventricular, intermediate, and mantle layers; and hair follicles with hair shafts (Fig. 5).
The essential characteristics that define R278.5 cells as ES cells include: indefinite (greater than one year) undifferentiated proliferation in vitro, normal karyotype, and potential to differentiate to derivatives of trophectoderm and all three embryonic germ layers. In the mouse embryo, the last cells capable of contributing to derivatives of both trophectoderm and ICM are early ICM cells. The timing of commitment to ICM or trophectoderm has not been established for any primate species, but the .~- WO 96/22362 2 1 a 0528 PCT/US96/00596 potential of rhesus ES cells to contribute to derivatives of both suggests that they most closely resemble early totipotent embryonic cells. The ability of rhesus ES cells to form trophoblast in vitro distinguishes primate ES cell lines from mouse ES cells. Mouse ES cell have not been demonstrated to form trophoblast in vitro, and mouse trophoblast does not produce gonadotropin. Rhesus ES cells and mouse ES cells do demonstrate the similar wide range of differentiation in tumors that distinguishes ES
cells from EC cells. The development of structures composed of multiple cell types such as hair follicles, which require inductive interactions between the embryonic epidermis and underlying mesenchyme, demonstrates the ability of rhesus ES
cells to participate in complex developmental processes.
The rhesus ES lines R366 and R367 have also been further cultured and analyzed. Both lines have a normal XY karyotype and were proliferated in an undifferentiated state for about three months prior to freezing for later analysis. Samples of each of the cell lines R366 and R367 were injected into SCID
mice which then formed teratomas identical to those formed by R278.5 cells. An additional rhesus cell line R394 having a normal XX karyotype was also recovered. All three of these cell lines, R366, R367 and R394 are identical in morphology, growth characteristics, culture requirements and in vitro differentiation characteristics, i.e. the trait of differentiation to multiple cell types in the absence of fibroblasts, to cell line 278.5.
It has been determined that LIF is not required either to derive or proliferate these ES cultures.
Each of the cell lines R366, R367 and R394 were derived and cultured without exogenous LIF.
It has also been demonstrated that the WO 96/22362 2 19 Uj L 8 PCT/US96/00596 particular source of fibroblasts for co-culture is not critical. Several fibroblast cell lines have been tested both with rhesus line R278.5 and with the marmoset cell lines described below. The fibroblasts tested include mouse STO cells (ATCC 56-X), mouse 3T3 cells (ATCC 48-X), primary rhesus monkey embryonic fibroblasts derived from 36 day rhesus fetuses, and mouse S1/S14 cells, which are deficient in the steel factor. All these fibroblast cell lines were capable of maintaining the stem cell lines in an undifferentiated state. Most rapid proliferation of the stem cells was observed using primary mouse embryonic fibroblasts.
Unlike mouse ES cells, neither rhesus ES cells nor feeder-dependent human EC cells remain undifferentiated and proliferate in the presence of soluble human LIF without fibroblasts. The factors that fibroblasts produce that prevent the differentiation of rhesus ES cells or feeder-dependent human EC cells are unknown, but the lack of a dependence on LIF is another characteristic that distinguishes primate ES cells from mouse ES cells.
The growth of rhesus monkey ES cells in culture conditions similar to those required by feeder-dependent human EC cells, and the identical morphology and cell surface markers of rhesus ES
cells and human EC cells, suggests that similar culture conditions will support human ES cells.
Rhesus ES cells will be important for elucidating the mechanisms that control the differentiation of specific primate cell types.
Given the close evolutionary distance and the developmental and physiological similarities between humans and rhesus monkeys, the mechanisms controlling the differentiation of rhesus cells will be very similar to the mechanisms controlling the differentiation of human cells. The importance of elucidating these mechanisms is that once they are understood, it will be possible to direct primate ES
cells to differentiate to specific cell types in vitro, and these specific cell types can be used for transplantation to treat specific diseases.
Because ES cells have the developmental potential to give rise to any differentiated cell type, any disease that results in part or in whole from the failure (either genetic or acquired) of specific cell types will be potentially treatable through the transplantation of cells derived from ES
cells. Rhesus ES cells and rhesus monkeys will be invaluable for testing the efficacy and safety of the transplantation of specific cell types derived from ES cells. A few examples of human diseases potentially treatable by this approach with human ES
cells include degenerative neurological disorders such as Parkinson's disease (dopanergic neurons), juvenile onset diabetes (pancreatic (3-islet cells) or Acquired Immunodeficiency Disease (lymphocytes).
Because undifferentiated ES cells can proliferate indefinitely in vitro, they can be genetically manipulated with standard techniques either to prevent immune rejection after transplantation, or to give them new genetic properties to combat specific diseases. For specific cell types where immune rejection can be prevented, cells derived from rhesus monkey ES cells or other non-human primate ES cells could be used for transplantation to humans to treat specific diseases.

(3) Marmoset Embryonic Stem Cells Our method for creating an embryonic stem cell line is described above. Using isolated ICM's derived by immunosurgery from marmoset blastocysts, we have isolated 7 putative ES cell lines, each of which have been cultured for over 6 months.

WO 96/22362 2 1~ 0 5 2- 8 PCT/US96/00596 One of these, Cjll, was cultured continuously for over 14 months, and then frozen for later analysis. The Cjll cell line and other marmoset ES
cell lines have been successfully frozen and then thawed with the recovery of viable cells. These cells have a high nuclear/cytoplasmic ratio, prominent nucleoli, and a compact colony morphology similar to the pluripotent human embryonal carcinoma (EC) cell line NT2/D2.
Four of the cell lines we have isolated have normal XX karyotypes, and one has a normal XY
karyotype (Karyotypes were performed by Dr. Charles Harris, University of Wisconsin). These cells were positive for a series of cell surface markers (alkaline phosphatase, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81) that in combination are definitive markers for undifferentiated human embryonal carcinoma cells (EC) cells and primate ES cells. In particular, these markers distinguish EC cells from the earliest lineages to differentiate in the human preimplantation embryo, trophectoderm (represented by BeWO choriocarcinoma cells) and extraembryonic endoderm (represented by 1411H yolk sac carcinoma cells).
When the putative marmoset ES cells were removed from fibroblast feeders, they differentiated into cells of several distinct morphologies. Among the differentiated cells, trophectoderm is indicated by the secretion of chorionic gonadotropin and the presence of the chorionic gonadotropin 0-subunit mRNA. 12.7 mIU/ml luteinizing hormone (LH) activity was measured in the WRPRC core assay lab using a mouse Leydig cell bioassay in medium conditioned 24 hours by putative ES cells allowed to differentiate for one week. Note that chorionic gonadotrophin has both LH and FSH activity, and is routinely measured by LH assays. Control medium from undifferentiated 219~528 ES cells had less than 1 mIU/ml LH activity.
Chorionic gonadotropin 0-subunit mRNA was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). DNA sequencing confirmed the identity of the chorionic gonadotrophin 0-subunit.
Endoderm differentiation (probably extraembryonic endoderm) was indicated by the presence of a-fetoprotein mRNA, detected by RT-PCR.
When the marmoset ES cells were grown in high densities, over a period of weeks epithelial cells differentiated and covered the culture dish. The remaining groups of undifferentiated cells rounded up into compact balls and then formed embryoid bodies (as shown in Fig. 6) that recapitulated early development with remarkable fidelity. Over 3-4 weeks, some of the embryoid bodies formed a bilaterally symmetric pyriform embryonic disc, an amnion, a yolk sac, and a mesoblast outgrowth attaching the caudal pole of the amnion to the culture dish.
Histological and ultrastructural examination of one of these embryoid bodies (formed from a cell line that had been passaged continuously for 6 months) revealed a remarkable resemblance to a stage 6-7 post-implantation embryo. The embryonic disc was composed of a polarized, columnar epithelial epiblast (primitive ectoderm) layer separated from a visceral endoderm (primitive endoderm) layer. Electron microscopy of the epiblast revealed apical junctional complexes, apical microvilli, subapical intermediate filaments, and a basement membrane separating the epiblast from underlying visceral endoderm. All of these elements are features of the normal embryonic disc. In the caudal third of the embryonic disc, there was a midline groove, disruption of the basement membrane, and mixing of epiblast cells with underlying endodermal cells (early primitive streak).

WO 96/22362 PCI'/US96/00596 The amnion was composed of an inner squamous (ectoderm) layer continuous with the epiblast and an outer mesoderm layer. The bilayered yolk sac had occasional endothelial-lined spaces containing possible hematopoietic precursors.
The morphology, immortality, karyotype, and cell surface markers of these marmoset cells identify these marmoset cells as primate ES cells similar to the rhesus ES cells. Since the last cells in the mammalian embryo capable of contributing to both trophectoderm derivatives and endoderm derivatives are the totipotent cells of the early ICM, the ability of marmoset ES cells to contribute to both trophoblast and endoderm demonstrates their similarities to early totipotent embryonic cells of the intact embryo. The formation of embryoid bodies by marmoset ES cells, with remarkable structural similarities to the early post-implantation primate embryo, demonstrates the potential of marmoset ES
cells to participate in complex developmental processes requiring the interaction of multiple cell types.
Given the reproductive characteristics of the common marmoset described above (efficient embryo transfer, multiple young, short generation time), marmoset ES cells will be particularly useful for the generation of transgenic primates. Although mice have provided invaluable insights into gene function and regulation, the anatomical and physiological differences between humans and mice limit the usefulness of transgenic mouse models of human diseases. Transgenic primates, in addition to providing insights into the pathogenesis of specific diseases, will provide accurate animal models to test the efficacy and safety of specific treatments.
SEQUENCE LISTING
(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: Wisconsin Alumni Research Foundation (B) STREET: 614 North Walnut Street, P.O. Box 7365 (C) CITY: Madison (D) STATE: Wisconsin (E) COUNTRY: U.S.A.
(F) POSTAL CODE (ZIP): 53707-7365 (G) TELEPHONE: (416)368-2400 (H) TELEFAX: (416)363-8246 (ii) TITLE OF INVENTION: PRIMATE EMBRYONIC STEM CELLS
(iii) NUMBER OF SEQUENCES: 6 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: CA 2,190,528 (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/376,327 (B) FILING DATE: 20-JAN-1995 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) A

= .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear .~
(ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Claims (11)

CLAIMS:
1. Primate embryonic stem cells in culture which (i) will proliferate in an undifferentiated state in an in vitro culture for over one year, (ii) maintain a normal karyotype through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iv) will not differentiate when cultured on a fibroblast feeder layer.
2. The cells of claim 1 wherein the stem cells will spontaneously differentiate to trophoblast and produce chorionic gonadotropin when cultured beyond confluence.
3. Primate embryonic stem cells in culture wherein the cells are negative for SSEA-1 marker, positive for SSEA-3 marker, positive for SSEA-4 marker, express alkaline phosphatase activity, are pluripotent, retain normal karyotypes and will not differentiate when cultured on a fibroblast feeder layer.
4. The cells of claim 3 wherein the cells are positive for TRA-1-60, and TRA-1-81 markers.
5. The cells of claim 3 wherein the cells continue to proliferate in an undifferentiated state after continuous culture for at least one year.
6. The cells of claim 3 wherein the cells will differentiate to trophoblast when cultured beyond confluence and will produce chorionic gonadotropin.
7. The cells of claim 3 wherein the cells remain euploid for more than one year of continuous culture.
8. The cells of claim 3 wherein the cells differentiate into cells derived from mesoderm, endoderm and ectoderm germ layers when the cells are injected into a SCID mouse.
9. A method of isolating a primate embryonic stem cell line, comprising the steps of:
(a) isolating cells from the inner cell mass of a primate blastocyst;
(b) plating the inner cell mass cells on embryonic fibroblasts, wherein inner cell mass-derived cell masses are formed;
(c) dissociating the mass into dissociated cells;
(d) replating the dissociated cells on embryonic feeder cells;
(e) selecting colonies with compact morphologies and cells with high nucleus to cytoplasm ratios and prominant nucleoli;
and (f) culturing the cells of the selected colonies on a feeder layer to produce an isolated primate embryonic stem cell.
10. A method as claimed in claim 9 further comprising maintaining the isolated cells on a fibroblast feeder layer to prevent differentiation.
11. An isolated primate embryonic stem cell line developed by the method of claim 9, wherein the cell line is negative for SSEA-1 marker, positive for SSEA-3 marker, positive for SSEA-4 marker, express alkaline phosphatase activity, are pluripotent, retain normal karyotypes and will not differentiate when cultured on a fibroblast feeder layer.
CA2190528A 1995-01-20 1996-01-19 Primate embryonic stem cells Expired - Lifetime CA2190528C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37632795A 1995-01-20 1995-01-20
US08/376,327 1995-01-20
PCT/US1996/000596 WO1996022362A1 (en) 1995-01-20 1996-01-19 Primate embryonic stem cells

Publications (2)

Publication Number Publication Date
CA2190528A1 CA2190528A1 (en) 1996-07-25
CA2190528C true CA2190528C (en) 2010-04-27

Family

ID=23484566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2190528A Expired - Lifetime CA2190528C (en) 1995-01-20 1996-01-19 Primate embryonic stem cells

Country Status (5)

Country Link
US (11) US5843780A (en)
EP (2) EP1640448A3 (en)
AU (1) AU4758496A (en)
CA (1) CA2190528C (en)
WO (1) WO1996022362A1 (en)

Families Citing this family (806)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
US7153684B1 (en) * 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
EP0688358A4 (en) * 1993-03-12 1997-10-01 Univ Creighton Improved vectors for gene therapy
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
US9068164B1 (en) 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US7112440B2 (en) 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US20030190753A1 (en) * 1995-11-09 2003-10-09 Nature Technology Corporation Vectors for gene transfer
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
WO1997047734A1 (en) * 1996-06-14 1997-12-18 The Regents Of The University Of California In vitro derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
US20020194637A1 (en) * 2001-06-06 2002-12-19 University Of Massachussetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
US7696404B2 (en) * 1996-08-19 2010-04-13 Advanced Cell Technology, Inc. Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
CA2289277C (en) 1997-04-24 2013-02-12 University Of Washington Targeted gene modification by parvoviral vectors
WO1999001763A2 (en) * 1997-07-02 1999-01-14 Board Of Regents, The University Of Texas System p53 AS A REGULATOR OF CELL DIFFERENTIATION
JP3880795B2 (en) * 1997-10-23 2007-02-14 ジェロン・コーポレーション Method for growing primate-derived primordial stem cells in a culture that does not contain feeder cells
WO1999027076A1 (en) * 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
US20050096274A1 (en) * 1998-04-07 2005-05-05 Lough John W. Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
ES2246085T3 (en) 1998-05-07 2006-02-01 University Of South Florida OSEA MEDULA CELLS AS A SOURCE OF NEURONS USEFUL TO REPAIR THE SPINAL MEDULA AND THE BRAIN.
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6767737B1 (en) * 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
JP2002523084A (en) * 1998-09-01 2002-07-30 ウイスコンシン アラムニ リサーチ ファンデーション Primate embryonic stem cells with compatible histocompatibility genes
US6630349B1 (en) 1998-09-23 2003-10-07 Mount Sinai Hospital Trophoblast cell preparations
US20020168766A1 (en) * 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US7413904B2 (en) * 1998-10-23 2008-08-19 Geron Corporation Human embryonic stem cells having genetic modifications
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
JP2002529070A (en) * 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ Embryonic stem cells
GB9907243D0 (en) 1999-03-29 1999-05-26 Reneuron Ltd Therapy
US7759113B2 (en) * 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
DE60017900T2 (en) * 1999-04-30 2006-04-06 Massachusetts General Hospital, Boston PREPARATION OF THREE-DIMENSIONAL VASCULARIZED TISSUE BY USING TWO-DIMENSIONAL MICRO-MADE SHAPES
IL129966A (en) * 1999-05-14 2009-12-24 Technion Res & Dev Foundation ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1214404A4 (en) * 1999-09-14 2003-09-03 Univ Massachusetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
AUPQ307399A0 (en) * 1999-09-24 1999-10-21 Luminis Pty Limited Cell cycle control
EP1218489B1 (en) * 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1226239A4 (en) * 1999-10-15 2003-02-12 Advanced Cell Tech Inc Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells
US20030129745A1 (en) * 1999-10-28 2003-07-10 Robl James M. Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
BR0015264A (en) * 1999-11-02 2002-10-15 Univ Massachusetts Public Inst Use of haploid genomes for diagnosis, genetic modification and multiplication
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
WO2001043540A2 (en) * 1999-12-17 2001-06-21 Oregon Health And Science University Methods for producing transgenic animals
EP1248517A2 (en) * 2000-01-07 2002-10-16 Oregon Health and Science University Clonal propagation of primate offspring by embryo splitting
US20050042749A1 (en) * 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7455983B2 (en) * 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US20030134413A1 (en) * 2000-01-14 2003-07-17 Rathjen Peter David Cell production
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US7005252B1 (en) * 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US7226057B2 (en) * 2000-03-10 2007-06-05 Days Corporation Apparatus and method for automatically leveling an object
US6619693B1 (en) * 2000-03-10 2003-09-16 Days Corporation Apparatus and method for automatically leveling an object
US7504257B2 (en) * 2000-03-14 2009-03-17 Es Cell International Pte Ltd. Embryonic stem cells and neural progenitor cells derived therefrom
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7776021B2 (en) 2000-04-28 2010-08-17 The Charles Stark Draper Laboratory Micromachined bilayer unit for filtration of small molecules
NL1017973C2 (en) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Design.
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
US8273570B2 (en) * 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
CA2409698C (en) * 2000-05-17 2010-10-26 Geron Corporation Neural progenitor cell populations
US7270998B2 (en) * 2000-06-01 2007-09-18 Japan Science And Technology Corporation Method of concentrating and separating dopaminergic neurons
CA2411849A1 (en) * 2000-06-05 2001-12-13 The Burnham Institute Methods of differentiating and protecting cells by modulating the p38/mef2 pathway
CA2412361C (en) 2000-06-14 2011-08-23 Vistagen, Inc. Toxicity typing using liver stem cells
WO2001096532A2 (en) * 2000-06-15 2001-12-20 Tanja Dominko Method of generating pluripotent mammalian cells by fusion of a cytoplast fragment with a karyoplast
AU2001274540A1 (en) * 2000-06-15 2001-12-24 Tanabe Seiyaku Co., Ltd. Monkey-origin embryonic stem cells
JP5014535B2 (en) * 2000-06-15 2012-08-29 田辺三菱製薬株式会社 Cynomolgus monkey-derived embryonic stem cells
WO2001098463A1 (en) * 2000-06-20 2001-12-27 Es Cell International Pte Ltd Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists
IL154159A0 (en) 2000-08-01 2003-07-31 Yissum Res Dev Co Directed differentiation of ebryonic cells
WO2002014469A2 (en) * 2000-08-15 2002-02-21 Geron Corporation Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
AU2001284160A1 (en) * 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
AU785428B2 (en) 2000-08-30 2007-05-17 Maria Biotech Co., Ltd Human embryonic stem cells derived from frozen-thawed embryo
US6534052B1 (en) 2000-09-05 2003-03-18 Yong-Fu Xiao Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated
US6607720B1 (en) 2000-09-05 2003-08-19 Yong-Fu Xiao Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction
AU2001286222A1 (en) * 2000-09-14 2002-03-26 Atsushi Yuki Process for producing normal parenchymal cells, tissue or organ by bioincubator
AUPR095200A0 (en) * 2000-10-24 2000-11-16 Bresagen Limited Cell production
AU1368402A (en) * 2000-11-09 2002-05-21 Bresagen Ltd Cell reprogramming
JP2004521877A (en) * 2000-11-22 2004-07-22 ジェロン コーポレイション Pluripotent stem cell allograft tolerization
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US20030027331A1 (en) * 2000-11-30 2003-02-06 Yan Wen Liang Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
EP1395652A2 (en) * 2000-11-30 2004-03-10 Stemron, Inc. Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
US20020068046A1 (en) * 2000-12-04 2002-06-06 Jianwu Dai Use of stem cells derived from dermal skin
WO2002063938A2 (en) * 2000-12-05 2002-08-22 Layton Bioscience Inc. Production and use of dopaminergic cells to treat dopaminergic deficiencies
WO2002053193A2 (en) 2001-01-02 2002-07-11 The Charles Stark Draper Laboratory, Inc. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
NZ568250A (en) 2001-01-02 2009-07-31 Stemron Inc A method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
JP2004529621A (en) * 2001-02-14 2004-09-30 ティー ファークト,レオ Pluripotent adult stem cells, their origin, methods of obtaining and maintaining them, methods of differentiating them, methods of their use, and cells derived therefrom
AUPR349501A0 (en) * 2001-03-02 2001-03-29 Bresagen Limited Cellular production control
US7126039B2 (en) * 2001-03-21 2006-10-24 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
WO2002079457A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
US20050176665A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
WO2003004605A2 (en) * 2001-07-06 2003-01-16 Geron Corporation Mesenchymal cells and osteoblasts from human embryonic stem cell
US7732199B2 (en) 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
KR101073411B1 (en) * 2001-07-12 2011-10-17 제론 코포레이션 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US20030017587A1 (en) * 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10136719A1 (en) * 2001-07-27 2003-02-20 Georg S Wengler Recovering omnipotent human embryonic stem cells, comprises separating them from a blastocyte which remains viable, useful for gene therapy especially autotransplants
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
US20040092013A1 (en) * 2001-08-14 2004-05-13 Snyder Evan Y. Method of treating alzheimer's disease with cell therapy
US20030211603A1 (en) * 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
CA2458362A1 (en) * 2001-08-23 2003-03-06 Reliance Life Sciences Pvt., Ltd. Isolation of inner cell mass for the establishment of human embryonic stem cell (hesc) lines
DE10144326B4 (en) * 2001-09-10 2005-09-22 Siemens Ag Method and system for monitoring a tire air pressure
US7588937B2 (en) 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US6887706B2 (en) * 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
US8153424B2 (en) * 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
EP1446476A4 (en) * 2001-11-02 2005-01-26 Wisconsin Alumni Res Found Endothelial cells derived from primate embryonic stem cells
US6759244B2 (en) * 2001-11-08 2004-07-06 Art Institute Of New York And New Jersey, Inc. Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
WO2003054146A2 (en) * 2001-11-14 2003-07-03 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
DE60233248D1 (en) * 2001-11-15 2009-09-17 Childrens Medical Center PROCESS FOR THE ISOLATION, EXPANSION AND DIFFERENTIATION OF FEDERAL STRAIN CELLS FROM CHORION ZOTTE, FRUIT WATER AND PLAZENTA AND THERAPEUTIC USES THEREOF
CA2469483C (en) 2001-12-07 2017-07-25 Geron Corporation Hematopoietic cells from human embryonic stem cells
AU2002366602B2 (en) * 2001-12-07 2008-07-03 Asterias Biotherapeutics, Inc. Chondrocyte precursors derived from human embryonic stem cells
US7799324B2 (en) * 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
EP1463798A4 (en) * 2001-12-07 2005-01-19 Geron Corp Islet cells from human embryonic stem cells
US20040224403A1 (en) * 2001-12-07 2004-11-11 Robarts Research Institute Reconstituting hematopoietic cell function using human embryonic stem cells
US20030113910A1 (en) * 2001-12-18 2003-06-19 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue
AU2002357410A1 (en) 2001-12-21 2003-07-09 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
CN1671835A (en) * 2001-12-28 2005-09-21 塞拉提斯股份公司 A method for the establishment of a pluripotent human blastocyst-derived stem cell line
US7190781B2 (en) * 2002-01-04 2007-03-13 Telefonaktiebolaget Lm Ericsson (Publ) Message transfer part point code mapping method and node
US20040043482A1 (en) * 2002-01-04 2004-03-04 Kye-Hyung Paik Method of producing stem cell lines
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20050090004A1 (en) * 2003-01-16 2005-04-28 Sayre Chauncey B. Stem cell maturation for all tissue lines
US20030134422A1 (en) * 2002-01-16 2003-07-17 Sayre Chauncey Bigelow Stem cell maturation for all tissue lines
US20030162290A1 (en) * 2002-01-25 2003-08-28 Kazutomo Inoue Method for inducing differentiation of embryonic stem cells into functioning cells
EP1471140A4 (en) * 2002-01-31 2005-02-16 Asahi Techno Glass Cosporation Liquid for frozen storage of primate embryo stem cells and frozen storage method
WO2003066839A1 (en) * 2002-02-05 2003-08-14 Rappaport Family Institute For Research In The Medical Sciences Lineage committed stem cells selected for telomerase promoter activity
US20050106724A1 (en) * 2002-02-06 2005-05-19 Joerg Schierholz Pluripotent embryonic-like stem cells derived from teeth and uses thereof
US7371719B2 (en) * 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US7736892B2 (en) * 2002-02-25 2010-06-15 Kansas State University Research Foundation Cultures, products and methods using umbilical cord matrix cells
US20030161818A1 (en) * 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
WO2003078967A2 (en) * 2002-03-12 2003-09-25 Oregon Health & Science University Stem cell selection and differentiation
AU2002246132A1 (en) * 2002-03-13 2003-09-22 Fundacion Ivi Para El Estudio De La Reproduccion Humana (Fivier) Method of producing cell lines
IL163949A0 (en) * 2002-03-15 2005-12-18 Wisconsin Alumni Res Found Method of identifying genes controlling differentiation
JP4264360B2 (en) 2002-03-15 2009-05-13 ウィセル リサーチ インスティテュート インコーポレイテッド Production method of primate trophoblast
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
US20040111285A1 (en) * 2002-04-09 2004-06-10 Mark Germain Method for human pluripotent stem cells
CA2484223A1 (en) * 2002-04-25 2003-11-06 Wisconsin Alumni Research Foundation Use of human neural stem cells secreting gdnf for treatment of parkinson's and other neurodegenerative diseases
US20030207448A1 (en) * 2002-05-06 2003-11-06 Revera Gregory Henry Methodologies for the creation of pluripotent or multipotent human stem cells without creating or destroying a human embryo
US6816665B2 (en) * 2002-05-09 2004-11-09 Lynx Photonic Networks Inc. Constant power operation thermo-optic switch
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
US7763466B2 (en) * 2002-05-17 2010-07-27 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
WO2003100018A2 (en) 2002-05-24 2003-12-04 Advanced Cell Technology, Inc. A bank of stem cells for transplantation
AU2003247514A1 (en) * 2002-06-11 2003-12-22 Roy Ogle Meningeal-derived stem cells
EP1558086A4 (en) * 2002-06-14 2008-03-05 Univ Case Western Reserve Cell targeting methods and compositions
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US20050101014A1 (en) * 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
WO2007116408A2 (en) * 2006-04-11 2007-10-18 Nanodiagnostics Israel Ltd. Pluripotent stem cells characterized by expression of germline specific genes
US20110158966A1 (en) * 2002-07-23 2011-06-30 Judith Seligman Stem cells characterized by expression of germline specific genes
AU2003247135A1 (en) * 2002-07-23 2004-02-09 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
US8876532B2 (en) 2002-07-31 2014-11-04 Dentsply International Inc. Bone repair putty
AU2003254298A1 (en) 2002-08-02 2004-02-23 Stratatech Corporation Species specific dna detection
US20060121607A1 (en) * 2002-08-08 2006-06-08 Thomas Schulz Compositions and methods for neural differentiation of embryonic stem cells
IL166636A0 (en) * 2002-08-09 2006-01-15 Innovationsagentur Method for producing cell lines and organs by means of differentiable cells
AU2003262760A1 (en) 2002-08-21 2004-03-11 Northwestern University Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
US20040058310A1 (en) * 2002-09-20 2004-03-25 Grailhe Regls Christian Method for measuring a marker indicative of the exposure of a patient to nicotine; a kit for measuring such a marker
WO2004029203A2 (en) * 2002-09-25 2004-04-08 Bresagen, Inc. Compositions and methods for enrichment of neural stem cells using ceramide analogs
US7267981B2 (en) 2002-10-07 2007-09-11 Technion Research & Development Foundation Ltd. Human foreskin fibroblasts for culturing ES cells
CN1717478A (en) * 2002-10-25 2006-01-04 湖南惠霖生命科技有限公司 Be used for the feeder layer of hESC's vitro culture and the method for cultivating embryonic stem cell
US7554021B2 (en) * 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
US7683025B2 (en) 2002-11-14 2010-03-23 Northwestern University Synthesis and self-assembly of ABC triblock bola peptide amphiphiles
WO2004050826A2 (en) * 2002-11-29 2004-06-17 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
US20040110286A1 (en) * 2002-12-06 2004-06-10 The John P. Robarts Research Institute Method for making hematopoietic cells
HUE028026T2 (en) 2002-12-16 2016-11-28 Technion Res & Dev Foundation Feeder-free, xeno-free culture system for human embryonic stem cells
AU2003303741A1 (en) * 2002-12-18 2004-09-17 Bresagen, Inc. Compositions and methods for neural cell production and stabilization
WO2004065616A2 (en) 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
WO2004072104A2 (en) * 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
BRPI0408733A (en) * 2003-03-12 2006-03-07 Reliance Life Sciences Pvt Ltd derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
US20030224411A1 (en) * 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US7153650B2 (en) * 2003-03-13 2006-12-26 Geron Corporation Marker system for preparing and characterizing high-quality human embryonic stem cells
US20070020242A1 (en) * 2003-03-27 2007-01-25 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway
US20040191839A1 (en) * 2003-03-28 2004-09-30 National Institute Of Agrobiological Sciences Japan Methods for sorting undifferentiated cells and uses thereof
JP4502317B2 (en) * 2003-03-28 2010-07-14 独立行政法人農業生物資源研究所 Method for selecting undifferentiated cells and use thereof
JP2004298108A (en) * 2003-03-31 2004-10-28 Japan Science & Technology Agency Method for producing lens cell, and lens cell obtained by the method
CA2520023C (en) 2003-04-08 2013-02-05 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
FR2853551B1 (en) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM
EP1615492A4 (en) * 2003-04-09 2010-07-14 Magee Womens Health Corp Methods for correcting mitotic spindle defects associated with somatic cell nuclear transfer in animals
US20060037086A1 (en) * 2003-04-09 2006-02-16 Schatten Gerald P Methods for correcting mitotic spindle defects and optimizing preimplantation embryonic developmental rates associated with somatic cell nuclear transfer in animals
IL155783A (en) 2003-05-05 2010-11-30 Technion Res & Dev Foundation Multicellular systems of pluripotent human embryonic stem cells and cancer cells and uses thereof
WO2004099394A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for efficient transfer of human blastocyst-derived stem cells (hbs cells) from a feeder-supported to a feeder-free culture system
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
US20090203141A1 (en) * 2003-05-15 2009-08-13 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents
US9567591B2 (en) 2003-05-15 2017-02-14 Mello Biotechnology, Inc. Generation of human embryonic stem-like cells using intronic RNA
WO2005034624A2 (en) 2003-05-21 2005-04-21 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
EP1702062A2 (en) * 2003-06-11 2006-09-20 Jan Remmereit Differentiation of stem cells for therapeutic use
WO2004108882A2 (en) * 2003-06-11 2004-12-16 Yeda Research And Development Co. Ltd. Neural stem cells and methods of generating and utilizing same
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US20050019907A1 (en) * 2003-07-22 2005-01-27 Santiago Munne Obtaining normal disomic stem cells from chromosomally abnormal embryos
EP3473102A1 (en) 2003-08-01 2019-04-24 Stratatech Corporation Methods for providing human skin equivalents
US7569385B2 (en) * 2003-08-14 2009-08-04 The Regents Of The University Of California Multipotent amniotic fetal stem cells
US7820439B2 (en) * 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
US20050054100A1 (en) * 2003-09-08 2005-03-10 Rennard Stephen I. Methods for fibroblast differentiation
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
WO2005032251A1 (en) * 2003-10-09 2005-04-14 I.M.T. Interface Multigrad Technology Ltd. Method for freezing, thawing and transplantation of viable cartilage
US20050100924A1 (en) * 2003-11-06 2005-05-12 National University Of Singapore C/EBPalpha gene targeting constructs and uses thereof
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20050123525A1 (en) * 2003-11-13 2005-06-09 Ulrich Martin Composition and method for inducing immune tolerance towards cell, tissue and/or organ transplants
US20080220520A1 (en) * 2003-11-19 2008-09-11 Palecek Sean P Cryopreservation of human embryonic stem cells in microwells
US20050106554A1 (en) * 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
US20050106725A1 (en) * 2003-11-19 2005-05-19 Palecek Sean P. Method of reducing cell differentiation
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
US7682828B2 (en) * 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7632681B2 (en) * 2003-12-02 2009-12-15 Celavie Biosciences, Llc Compositions and methods for propagation of neural progenitor cells
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
CA2549391A1 (en) * 2003-12-05 2005-06-23 Northwestern University Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
CA2549164A1 (en) * 2003-12-05 2005-06-23 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
TWI280280B (en) * 2003-12-09 2007-05-01 Ind Tech Res Inst Culture system and method for expansion and undifferentiated growth of human embryonic stem cells
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US20050214257A1 (en) 2003-12-23 2005-09-29 Northwestern University Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
CN103898045B (en) 2003-12-23 2019-02-01 维亚希特公司 Definitive entoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
WO2005065354A2 (en) * 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
US20060112438A1 (en) 2004-01-02 2006-05-25 West Michael D Novel culture systems for ex vivo development
AU2005209169B2 (en) 2004-01-16 2010-12-16 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20080241107A1 (en) * 2004-01-23 2008-10-02 Copland Iii John A Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells
US20050186672A1 (en) * 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
US8196416B2 (en) * 2004-02-02 2012-06-12 Core Dynamics Limited Device for directional cooling of biological matter
EP1711053A2 (en) * 2004-02-02 2006-10-18 I.M.T. Interface Multigrad Technology Ltd. Biological material and methods and solutions for preservation thereof
WO2005080551A2 (en) * 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
KR20080036636A (en) * 2004-02-26 2008-04-28 리라이언스 라이프 사이언시스 프라이빗. 리미티드 Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
US8187875B2 (en) 2004-02-26 2012-05-29 Reliance Life Sciences Pvt. Ltd. Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof
US20050214938A1 (en) * 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US7670596B2 (en) 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
GB2428044B (en) * 2004-05-07 2008-08-06 Wisconsin Alumni Res Found Method of forming mesenchymal stem cells from embryonic stem cells
ATE460947T1 (en) * 2004-06-07 2010-04-15 Core Dynamics Ltd METHOD FOR STERILIZING BIOLOGICAL PREPARATIONS
EP3000877B1 (en) * 2004-06-09 2019-08-14 The University Court of the University of Edinburgh Neural stem cells
US20060008451A1 (en) * 2004-07-06 2006-01-12 Michigan State University In vivo methods for effecting tissue specific differentiation of embryonic stem cells
NZ582597A (en) 2004-07-09 2011-08-26 Viacyte Inc Preprimitive streak and mesendoderm cells
JP5687816B2 (en) 2004-07-09 2015-03-25 ヴィアサイト,インコーポレイテッド Methods for identifying factors for differentiating definitive endoderm
AU2005271723B2 (en) 2004-07-13 2010-12-16 Asterias Biotherapeutics, Inc. Medium for growing human embryonic stem cells
EP1781776A2 (en) * 2004-07-29 2007-05-09 Stem Cell Innovations, Inc. Differentiation of stem cells
US8037696B2 (en) * 2004-08-12 2011-10-18 Core Dynamics Limited Method and apparatus for freezing or thawing of a biological material
MX2007001772A (en) * 2004-08-13 2007-07-11 Univ Georgia Res Found Compositions and methods for self-renewal and differentiation in human embryonic stem cells.
WO2006025802A1 (en) * 2004-09-03 2006-03-09 Agency For Science, Technology And Research Method for maintaining pluripotency of stem/progenitor cells
US20060177926A1 (en) * 2004-09-07 2006-08-10 Erika Sasaki Common marmoset embryonic stem cell lines
CA2580754A1 (en) * 2004-09-21 2006-03-30 Nvr Labs, Ltd. Compositions and methods for stem cell expansion and differentiation
ATE373081T1 (en) * 2004-09-30 2007-09-15 Reneuron Ltd CELL LINE
US20070077654A1 (en) * 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
US7893315B2 (en) * 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
WO2006053378A1 (en) * 2004-11-16 2006-05-26 Sydney Ifv Limited Derivation and culture of human embryo-derived cells
CN104042629A (en) 2004-11-17 2014-09-17 神经干公司 Transplantation of human neural cells for treatment of neurodegenerative conditions
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060166361A1 (en) * 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
EP1833496B1 (en) 2004-12-23 2013-07-31 Ethicon, Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
DE102004062184B4 (en) * 2004-12-23 2013-08-01 Wolfgang Würfel Embryo-preserving production of pluripotent embryonic stem cells, stem cells thus obtained and use thereof
ES2621847T3 (en) 2004-12-23 2017-07-05 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using them
EP1838843B1 (en) 2004-12-23 2019-07-10 Viacyte, Inc. Expansion of definitive endoderm cells
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP1844136B1 (en) * 2004-12-29 2014-08-27 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
EP1841857A1 (en) * 2004-12-30 2007-10-10 Stemlifeline, Inc. Methods and compositions relating to embryonic stem cell lines
WO2006073966A1 (en) * 2004-12-30 2006-07-13 Stemlifeline, Inc. Methods and systems relating to embryonic stem cell lines
AU2006206194A1 (en) * 2005-01-21 2006-07-27 Northwestern University Methods and compositions for encapsulation of cells
US7022518B1 (en) * 2005-01-31 2006-04-04 Glen Feye Apparatus and method for co-culturing of cells
WO2006084314A1 (en) * 2005-02-09 2006-08-17 Australian Stem Cell Centre Limited Stem cell populations and classification system
EP1850661A2 (en) * 2005-02-22 2007-11-07 Interface Multigrad Technology (IMT) Ltd. Preserved viable cartilage, method for its preservation, and system and devices used therefor
JP2008531733A (en) * 2005-03-04 2008-08-14 ノースウエスタン ユニバーシティ Angiogenic heparin-binding epitopes, peptide amphiphiles, self-assembling compositions, and related uses
US20070048865A1 (en) * 2005-03-15 2007-03-01 Kenzaburo Tani Method for acceleration of stem cell differentiation
US9295543B2 (en) 2005-03-17 2016-03-29 Stratatech Corporation Skin substitutes with improved purity
US8012751B2 (en) * 2005-03-31 2011-09-06 Wisconsin Alumni Research Foundation Differentiation of pluripotent embryonic stem cells
US7883847B2 (en) 2005-04-01 2011-02-08 Wake Forest University Health Sciences Transcriptional profiling of stem cells and their multilineage differentiation
CN101180389A (en) * 2005-05-17 2008-05-14 利莱恩斯生命科学有限公司 Establishment of a human embryonic stem cell line using mammalian cells
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CA2613889A1 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
US20060292695A1 (en) * 2005-06-22 2006-12-28 Roslin Institute Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells
US20060292694A1 (en) * 2005-06-22 2006-12-28 Roslin Institute Reporter hepatocytes and other cells for drug screening and toxicity testing
US20080152632A1 (en) * 2005-06-22 2008-06-26 Roslin Institute Promoter-reporter cells for determining drug metabolism, drug interactions, and the effects of allotype variation
US9062289B2 (en) 2005-06-22 2015-06-23 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
KR20130100221A (en) 2005-06-22 2013-09-09 제론 코포레이션 Suspension culture of human embryonic stem cells
US20070026520A1 (en) * 2005-07-29 2007-02-01 Kelly James H Novel cells, compositions, and methods
US8198085B2 (en) * 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
AU2006286149B2 (en) 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
EP1940423B1 (en) 2005-09-09 2014-04-16 Duke University Tissue engineering methods and compositions
CA2869687C (en) 2005-10-27 2024-01-23 Viacyte, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
US7413900B2 (en) * 2005-10-31 2008-08-19 President And Fellows Of Harvard College Immortalized fibroblasts
CN101374537B (en) 2005-11-10 2016-04-20 健能万生物制药公司 The MNTF differentiation of stem cell and growth
US7521221B2 (en) * 2005-11-21 2009-04-21 Board Of Trustees Of The University Of Arknasas Staphylococcus aureus strain CYL1892
PL2535403T3 (en) 2005-12-08 2019-10-31 Univ Louisville Res Found Inc Very small embryonic-like (VSEL) stem cells and methods of isolating and using the same
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
CN101864392B (en) * 2005-12-13 2016-03-23 国立大学法人京都大学 Nuclear reprogramming factor
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP1971681B1 (en) 2005-12-16 2017-08-23 DePuy Synthes Products, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
ES2391034T3 (en) 2005-12-19 2012-11-20 Ethicon, Inc. In vitro expansion of postpartum derived cells in rotary bottles
JP5599568B2 (en) * 2005-12-28 2014-10-01 エシコン・インコーポレイテッド Treatment of peripheral vascular disease using postpartum-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
DK2420565T3 (en) 2006-02-23 2017-12-04 Viacyte Inc APPLICABLE COMPOSITIONS AND METHODS FOR CULTIVATING DIFFERENTIBLE CELLS
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
EP4112718A1 (en) * 2006-03-02 2023-01-04 ViaCyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
JP5468782B2 (en) 2006-03-02 2014-04-09 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Methods for cancer treatment and stem cell regulation
MX347303B (en) 2006-03-07 2017-04-21 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation.
WO2007106351A2 (en) * 2006-03-10 2007-09-20 The University Of Rochester Porous silicon materials and devices
SE0850071L (en) * 2006-04-10 2008-12-19 Wisconsin Alumni Res Found Reagents and methods for using human embryonic stem cells to evaluate the toxicity of pharmaceutical compounds and other chemicals.
EP2010646A2 (en) * 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
AU2007314614A1 (en) * 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
CA2646491A1 (en) 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
WO2007127927A2 (en) 2006-04-28 2007-11-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
BRPI0710949A2 (en) * 2006-04-28 2012-03-06 Asubio Pharma Co., Ltd. METHOD FOR INDUCING PLURIPOTENT STEM CELL DIFFERENTIATION IN CARDIOMYOCYTES
US7989204B2 (en) * 2006-04-28 2011-08-02 Viacyte, Inc. Hepatocyte lineage cells
US8877253B2 (en) * 2006-05-11 2014-11-04 Regenics As Cellular extracts
RU2421208C2 (en) 2006-05-11 2011-06-20 Ридженикс Ас Cell and cell extract introduction for rejuvenation
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
WO2007149926A1 (en) * 2006-06-20 2007-12-27 Wisconsin Alumni Research Foundation Method for culturing stem cells
US20080003676A1 (en) * 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
KR101335884B1 (en) 2006-07-24 2013-12-12 인터내셔날 스템 셀 코포레이션 Synthetic cornea from retinal stem cells
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
CA2661232A1 (en) * 2006-08-31 2008-03-06 The University Of Louisville Research Foundation, Inc. Transcription factors for differentiation of adult human olfactory progenitor cells
US20100323442A1 (en) * 2006-10-17 2010-12-23 Emmanuel Edward Baetge Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
US20080108044A1 (en) * 2006-11-08 2008-05-08 Deepika Rajesh In vitro differentiation of hematopoietic cells from primate embryonic stem cells
EP2087101A2 (en) * 2006-11-24 2009-08-12 Regents of the University of Minnesota Endodermal progenitor cells
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
JP2010516240A (en) 2007-01-18 2010-05-20 スオメン プナイネン リスティ,ヴェリパルベル Novel carbohydrates from human cells and methods for their analysis and modification
EP2108043A4 (en) 2007-01-18 2010-04-21 Suomen Punainen Risti Veripalv Novel methods and reagents directed to production of cells
US8084023B2 (en) 2007-01-22 2011-12-27 The Board Of Trustees Of The University Of Arkansas Maintenance and propagation of mesenchymal stem cells
EP2126045A4 (en) * 2007-01-30 2010-05-26 Univ Georgia Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
WO2008121437A2 (en) * 2007-02-08 2008-10-09 The Burnham Institute For Medical Research Trophinin-binding peptides and uses thereof
JP2010518857A (en) 2007-02-23 2010-06-03 アドバンスド セル テクノロジー, インコーポレイテッド A highly efficient method for the reprogramming of differentiated cells and the generation of animal and embryonic stem cells from the reprogrammed cells
CA2684242C (en) 2007-03-23 2019-11-12 Wisconsin Alumni Research Foundation Somatic cell reprogramming
EP2129771B1 (en) 2007-03-26 2018-09-12 The Government of the U.S.A. as represented by the Secretary of the Department of Health & Human Services Methods for modulating embryonic stem cell differentiation
US20080267874A1 (en) * 2007-03-28 2008-10-30 The Buck Institute For Age Research Targeted Neuronal And Glial Human Embryonic Stem Cell Line
CA2683056C (en) * 2007-04-07 2020-03-24 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
EP2554661B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
CN101720355A (en) * 2007-06-07 2010-06-02 福田惠一 Method of inducing differentiation into myocardial cells using g-csf
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
KR20160005142A (en) 2007-06-29 2016-01-13 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Automated method and apparatus for embryonic stem cell culture
CN101978044B (en) * 2007-07-01 2017-10-24 生命扫描有限公司 Single pluripotent stem cell culture
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US8227610B2 (en) * 2007-07-10 2012-07-24 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
EP2562248B1 (en) 2007-07-18 2021-06-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
WO2009048675A1 (en) 2007-07-31 2009-04-16 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
EP2610336A1 (en) 2007-07-31 2013-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
US20110105393A1 (en) 2007-08-16 2011-05-05 Andreas Androutsellis-Theotokis Methods for promoting stem cell proliferation and survival
CN101855338B (en) 2007-08-31 2013-07-17 怀特黑德生物医学研究所 WNT pathway stimulation in reprogramming somatic cells
US10925903B2 (en) 2007-09-13 2021-02-23 Reprobiogen Inc. Use of cells derived from first trimester umbilical cord tissue
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US20110236971A2 (en) * 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
UA99152C2 (en) 2007-10-05 2012-07-25 Этикон, Инкорпорейтед Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8623650B2 (en) * 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
EP2214497A4 (en) * 2007-10-30 2010-11-24 Univ Louisville Res Found Uses and isolation of very small embryonic-like (vsel) stem cells
JP5710264B2 (en) 2007-11-27 2015-04-30 ライフスキャン・インコーポレイテッドLifescan,Inc. Differentiation of human embryonic stem cells
EP2235161A1 (en) * 2007-12-11 2010-10-06 Research Development Foundation Small molecules for neuronal differentiation of embryonic stem cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
EP2240536B1 (en) * 2008-01-30 2019-09-04 Asterias Biotherapeutics, Inc. Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
KR20110005682A (en) 2008-01-30 2011-01-18 제론 코포레이션 Synthetic surfaces for culturing stem cell derived cardiomyocytes
US10071185B2 (en) * 2008-02-07 2018-09-11 Nayacure Therapeutics Ltd. Compartmental extract compositions for tissue engineering
US20090202978A1 (en) * 2008-02-13 2009-08-13 Ginadi Shaham Method and apparatus for freezing of a biological material
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US20100087002A1 (en) * 2008-02-21 2010-04-08 Benjamin Fryer Methods, Surface Modified Plates and Compositions for Cell Attachment, Cultivation and Detachment
EP2100954A1 (en) 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
DE102008013854A1 (en) * 2008-03-12 2009-09-24 Siemens Aktiengesellschaft Catheter and associated medical examination and treatment facility
US8716018B2 (en) 2008-03-17 2014-05-06 Agency For Science, Technology And Research Microcarriers for stem cell culture
AU2009225665B9 (en) * 2008-03-17 2015-01-15 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US8093049B2 (en) 2008-03-27 2012-01-10 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
DK2283117T3 (en) 2008-04-21 2014-01-20 Viacyte Inc PROCEDURE FOR CLEANING PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CN102027118B (en) 2008-04-30 2014-07-30 桑比欧公司 Neural regenerating cells with alterations in DNA methylation
US20110110863A1 (en) * 2008-05-02 2011-05-12 Celsense, Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
KR101661940B1 (en) 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Method of nuclear reprogramming
WO2009136867A1 (en) * 2008-05-06 2009-11-12 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
US9394538B2 (en) 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines
EP2297298A4 (en) * 2008-05-09 2011-10-05 Vistagen Therapeutics Inc Pancreatic endocrine progenitor cells derived from pluripotent stem cells
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2294187A2 (en) * 2008-05-21 2011-03-16 BioE LLC Differentiation of multi-lineage progenitor cells to pancreatic cells
EP2297319B1 (en) 2008-06-03 2015-10-07 Viacyte, Inc. Growth factors for production of definitive endoderm
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
KR101648019B1 (en) 2008-06-04 2016-08-16 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Methods for the production of iPS cells using non-viral approach
US9497943B2 (en) 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
US8871900B2 (en) 2008-06-16 2014-10-28 University Of Rochester Fibroblast growth factor (FGF) analogs and uses thereof
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
AU2009308967C1 (en) 2008-10-31 2017-04-20 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
KR101798474B1 (en) * 2008-10-31 2017-11-16 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
WO2010053472A1 (en) 2008-11-04 2010-05-14 Novocell, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US8956867B2 (en) * 2008-11-07 2015-02-17 Wisconsin Alumni Research Foundation Method for culturing stem cells
CA3229301A1 (en) * 2008-11-14 2010-05-20 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
BRPI0921996A2 (en) * 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Methods and compositions for culturing and binding cells on flat substrates.
ES2642070T3 (en) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivation of pluripotent stem cells in microcarriers
BRPI0922572A2 (en) 2008-12-17 2019-09-24 Scripps Research Inst method for culturing pluripotent cells, pluripotent mammalian cell culture, cell culture medium, isolated pluripotent animal cell, and method for increasing pluripotence of a mammalian cell.
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
BRPI0923070A2 (en) * 2008-12-19 2016-06-14 Atrm Llc "Uses of compositions for regeneration and repair of neural tissue after injury, said compositions, and kit"
WO2010071862A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
WO2010075500A1 (en) 2008-12-23 2010-07-01 Stemcells California, Inc Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2010084300A2 (en) 2009-01-22 2010-07-29 Iti Scotland Limited Stem cell culture methods
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
EP2233566A1 (en) 2009-03-17 2010-09-29 Vrije Universiteit Brussel Generation of pancreatic progenitor cells
ES2629003T3 (en) 2009-03-26 2017-08-07 DePuy Synthes Products, Inc. Human umbilical cord tissue cells as a treatment for Alzheimer's disease
GB0906424D0 (en) 2009-04-09 2009-05-20 Antoxis Ltd Use of compounds for differentiation of cells
WO2010120830A1 (en) * 2009-04-13 2010-10-21 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
US8193235B2 (en) * 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
KR20120065966A (en) 2009-06-12 2012-06-21 난양 폴리테크닉 Novel uses
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
WO2011005326A1 (en) 2009-07-09 2011-01-13 Massachusetts Institute Of Technology Methods and compositions for increased safety of stem cell-derived populations
CA2768643C (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2456859A4 (en) * 2009-07-20 2015-03-18 Janssen Biotech Inc Differentiation of human embryonic stem cells
WO2011011302A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
CN104962512B (en) 2009-07-21 2022-09-09 Abt控股公司 Use of stem cells for reducing leukocyte extravasation
DK2456860T3 (en) 2009-07-21 2019-01-07 Abt Holding Co USE OF STEM CELLS FOR REDUCING LEUKOCYTE EXTRAVASATION
DK2462230T3 (en) * 2009-08-03 2015-10-19 Recombinetics Inc METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
SG178365A1 (en) 2009-08-12 2012-04-27 Univ Kyoto Method for inducing differentiation of pluripotent stem cells into neural precursor cells
US20120148546A1 (en) 2009-08-17 2012-06-14 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
US8721521B2 (en) 2009-08-22 2014-05-13 The Board Of Trustees Of The Leland Stanford Junior University Imaging and evaluating embryos, oocytes, and stem cells
AU2010289423B2 (en) 2009-09-04 2014-03-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
WO2011056416A2 (en) 2009-10-19 2011-05-12 Cellular Dynamics International, Inc. Cardiomyocyte production
CN107058389A (en) * 2009-10-29 2017-08-18 詹森生物科技公司 Multipotential stem cell
EP2498796B1 (en) 2009-11-09 2017-12-27 AAL Scientifics, Inc. Treatment of heart disease
ES2932664T3 (en) 2009-11-12 2023-01-23 Technion Res & Dev Foundation Culture media, cell cultures and methods of culturing pluripotent stem cells in the undifferentiated state
CA2782577A1 (en) * 2009-12-02 2011-06-09 Research Development Foundation Selection of stem cell clones with defined differentiation capabilities
FI20096288A0 (en) 2009-12-04 2009-12-04 Kristiina Rajala Formulations and Methods for Culturing Stem Cells
WO2011072461A1 (en) 2009-12-18 2011-06-23 Shanghai He Chen Biotechnology Co., Ltd. Materials and methods for generating pluripotent stem cells
RU2610176C2 (en) 2009-12-23 2017-02-08 Янссен Байотек, Инк. Differentiation of human embryonic stem cells
CA2784425A1 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
EP2529008A1 (en) 2010-01-26 2012-12-05 Université Libre de Bruxelles Tools for isolating and following cardiovascular progenitor cells
WO2011099007A1 (en) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
BR112012021451B8 (en) 2010-02-25 2021-05-25 Abt Holding Co use of cells that have a desired efficiency for expression and/or secretion of the pro-angiogenic factors vegf, cxcl5 and il8, methods to build a cell bank, to develop drug, and to increase the expression of one or more pro-angiogenic factors angiogenic in a cell performed in vitro, and composition
WO2011106521A1 (en) 2010-02-25 2011-09-01 Abt Holding Company Modulation of macrophage activation
WO2011109279A2 (en) 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
US8662085B2 (en) 2010-03-02 2014-03-04 Siemens Aktiengesellschaft Magnetic nanoparticle and group of nanoparticles
AU2011232577C1 (en) 2010-03-22 2016-07-14 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
CN102906248A (en) 2010-03-25 2013-01-30 国际干细胞公司 Method of altering differentiative state of cell and compositions thereof
WO2011123572A1 (en) 2010-03-31 2011-10-06 The Scripps Research Institute Reprogramming cells
SG184440A1 (en) 2010-04-08 2012-11-29 Univ Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
JP5841322B2 (en) 2010-04-22 2016-01-13 オレゴン ヘルス アンド サイエンス ユニバーシティ Fumaryl acetoacetate hydrolase (FAH) deficient pig and use thereof
DK2561078T3 (en) 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
WO2011138687A2 (en) 2010-05-06 2011-11-10 Regenics As Use of cellular extracts for skin rejuvenation
CN102242146B (en) * 2010-05-10 2015-11-25 高丽大学校产学协力团 Composition and the method with its generation generate induced pluripotent stem cells
EP2568991B3 (en) 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
CN107338217B (en) 2010-05-12 2021-02-09 詹森生物科技公司 Differentiation of human embryonic stem cells
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2011158125A2 (en) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
AU2011268056B2 (en) 2010-06-18 2014-04-24 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
JP6660080B2 (en) 2010-07-01 2020-03-04 リジェネレイティブ リサーチ ファウンデーション Undifferentiated cell culture method using sustained release composition
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
EP2593117B1 (en) 2010-07-12 2019-03-20 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
US9121011B2 (en) 2010-07-21 2015-09-01 Kyoto University Method for inducing differentiation of human pluripotent stem cell into intermediate mesoderm cell
WO2012013969A1 (en) 2010-07-26 2012-02-02 The University Of Manchester Targeted differentiation of stem cells
WO2012014207A2 (en) * 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
US9144585B2 (en) 2010-07-27 2015-09-29 Technion Research & Development Foundation Limited Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
ES2571991T3 (en) 2010-07-28 2016-05-27 Neuralstem Inc Procedures for treating and / or reversing diseases and / or neurodegenerative disorders
KR20190027969A (en) 2010-08-12 2019-03-15 얀센 바이오테크 인코포레이티드 Treatment of diabetes with pancreatic endocrine precursor cells
CA2838330C (en) 2010-08-23 2021-01-26 President And Fellows Of Harvard College Optogenetic probes for measuring membrane potential
WO2012027474A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
ES2585028T3 (en) 2010-08-31 2016-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CA2809303A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP6168991B2 (en) 2010-08-31 2017-07-26 ヤンセン バイオテツク,インコーポレーテツド Differentiation of human embryonic stem cells
NZ607547A (en) 2010-09-01 2015-06-26 Univ Jefferson Composition and method for muscle repair and regeneration
DK2614141T3 (en) 2010-09-07 2019-09-09 Technion Res & Dev Foundation PRESENT PROCEDURES AND CULTIVATION MEDIA FOR CULTURING PLURIPOTENT STEM CELLS
US9617511B2 (en) 2010-09-07 2017-04-11 The Board Of Regents Of The University Of Texas System Tissue-specific differentiation matrices and uses thereof
CN103459611B (en) 2010-09-17 2016-11-02 哈佛大学校长及研究员协会 The functional genomics research that effectiveness and the safety of pluripotent stem cell are characterized
CA2812300A1 (en) 2010-10-01 2012-04-05 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Manipulation of stem cell function by p53 isoforms
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2012054896A1 (en) 2010-10-22 2012-04-26 Biotime Inc. Methods of modifying transcriptional regulatory networks in stem cells
CA2822638C (en) 2010-12-22 2021-02-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
WO2012091978A2 (en) 2010-12-31 2012-07-05 University Of Georgia Research Foundation, Inc. Differentiation of human pluripotent stem cells to multipotent neural crest cells
PL2667878T3 (en) 2011-01-25 2016-10-31 Compositions and methods for cell transplantation
US9102914B2 (en) 2011-02-03 2015-08-11 Empire Technology Development Llc 3D trophoblast matrix for preparing organ-specific stem cells
JP6005666B2 (en) 2011-02-08 2016-10-12 セルラー ダイナミクス インターナショナル, インコーポレイテッド Production of hematopoietic progenitor cells by programming
CA2827945C (en) 2011-02-23 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting aneuploidy in human embryos
EP2678425B1 (en) 2011-02-23 2017-08-23 Kyoto University Method for producing dendritic cells from pluripotent stem cells
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
KR102351944B1 (en) 2011-02-28 2022-01-18 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cell culture system
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US20140329314A1 (en) 2011-03-29 2014-11-06 Christopher O'Sullivan Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
JP5840855B2 (en) 2011-03-30 2016-01-06 学校法人東京女子医科大学 Method for producing myocardial sheet from embryonic stem cells
JP6185907B2 (en) 2011-03-30 2017-08-23 セルラー ダイナミクス インターナショナル, インコーポレイテッド Prestimulation of pluripotent stem cells for neural differentiation
US8785190B2 (en) 2011-04-06 2014-07-22 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
JP5745919B2 (en) * 2011-04-28 2015-07-08 浜松ホトニクス株式会社 Cell analysis method, cell analysis apparatus, and cell analysis program
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
AU2012266404B2 (en) 2011-06-06 2016-08-11 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
GB201110331D0 (en) 2011-06-16 2011-08-03 Isis Innovation Method of cryopreserving pluripotent stem cells
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
WO2013010965A1 (en) 2011-07-15 2013-01-24 Universite Libre De Bruxelles Generation of mesodermal cells from pluripotent stem cells
CA2841985C (en) 2011-07-29 2019-09-17 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
EP3578042A1 (en) 2011-08-26 2019-12-11 Yecuris Corporation Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
WO2013049856A2 (en) 2011-09-30 2013-04-04 Hare Joshue M Renal stem cells isolated from kidney
GB201117469D0 (en) 2011-10-10 2011-11-23 Cell Guidance Systems Ltd Culture media for pluripotent stem cells
EP2770051B1 (en) 2011-10-21 2017-09-27 ARKRAY, Inc. Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow
GB201119335D0 (en) 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
EP2594635A1 (en) 2011-11-18 2013-05-22 Univercell Biosolutions Method for generating primate cardiovascular progenitor cells for clinical and drug cells testing use from primate embryonic stem cells or embryonic-like state cells, and their applications
JP5999658B2 (en) 2011-11-25 2016-09-28 国立大学法人京都大学 Method for culturing pluripotent stem cells
WO2013082268A1 (en) 2011-11-30 2013-06-06 The Wistar Institute Of Anatomy And Biology Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming
CA2857295C (en) 2011-12-01 2021-06-29 New York Stem Cell Foundation Automated system for producing induced pluripotent stem cells or differentiated cells
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP3260140B1 (en) 2011-12-05 2021-02-03 Factor Bioscience Inc. Methods and products for transfecting cells
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
JP6143268B2 (en) 2011-12-19 2017-06-07 国立大学法人京都大学 Method for inducing differentiation from human pluripotent stem cells to intermediate mesoderm cells
KR102203056B1 (en) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells into single hormonal insulin positive cells
RU2636220C2 (en) 2011-12-23 2017-11-21 Депуи Синтез Продактс, Инк. Detection of cells obtained from umbilical cord tissue
EP2615176A1 (en) 2012-01-11 2013-07-17 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells
CA2861068C (en) 2012-01-13 2023-10-24 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
US9775890B2 (en) 2012-01-25 2017-10-03 Université Catholique de Louvain Factor Xa inhibitor used with liver-derived progenitor cells
EP2809152B1 (en) 2012-02-01 2019-11-20 Nayacure Therapeutics Ltd Method for inducing immune tolerance to organ transplants
EP3401394A1 (en) 2012-02-22 2018-11-14 Exostem Biotec Ltd Generation of neural stem cells
RU2664467C2 (en) 2012-03-07 2018-08-17 Янссен Байотек, Инк. Medium with defined composition for propagation and renewal of pluripotent stem cells
JP6112733B2 (en) 2012-04-06 2017-04-12 国立大学法人京都大学 Method for inducing erythropoietin-producing cells
SG10201809901SA (en) 2012-04-24 2018-12-28 Vcell Therapeutics Inc Generating Pluripotent Cells De Novo
KR20150004834A (en) 2012-04-24 2015-01-13 인터내셔날 스템 셀 코포레이션 Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
CA2871795C (en) 2012-04-30 2023-03-14 University Health Network Methods and compositions for generating pancreatic progenitors and functional beta cells from hpscs
JP5432322B2 (en) 2012-05-08 2014-03-05 株式会社大塚製薬工場 Mammalian cell suspension for prevention of pulmonary embolism containing trehalose
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
US20140017717A1 (en) 2012-05-31 2014-01-16 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
KR102468315B1 (en) 2012-06-08 2022-11-16 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells into pancreatic endocrine cells
CA2882028C (en) 2012-07-31 2023-11-07 Basil M. Hantash Human leukocyte antigen-g (hla-g) modified cells and methods
US20150216957A1 (en) 2012-08-20 2015-08-06 Boris Markosian Placental vaccination therapy for cancer
EP2900808B1 (en) 2012-09-28 2019-04-03 Scripps Health Methods of differentiating stem cells into chondrocytes
AU2013237760A1 (en) 2012-10-08 2014-04-24 Biotime, Inc. Differentiated progeny of clonal progenitor cell lines
US9974885B2 (en) 2012-10-29 2018-05-22 Scripps Health Methods of transplanting chondrocytes
EP2912166B1 (en) 2012-10-29 2019-05-01 Scripps Health Methods of producing pluripotent stem cells from chondrocytes
RU2019143431A (en) 2012-11-01 2020-04-28 Фэктор Байосайенс Инк. METHODS AND PRODUCTS FOR EXPRESSION OF PROTEINS IN CELLS
CN104822843B (en) 2012-11-02 2020-01-21 施特米纳生物标记研发公司 Predicting human developmental toxicity of drugs using human stem-like cells and metabolomic ratios
AU2013248265B2 (en) 2012-11-08 2018-11-01 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
WO2014091312A2 (en) 2012-12-10 2014-06-19 Regenics As Use of cellular extracts for skin rejuvenation
EP2938721B1 (en) 2012-12-28 2019-10-16 Kyoto University Method for inducing astrocytes
DK2938723T3 (en) 2012-12-31 2023-02-20 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS
CN105705634A (en) 2012-12-31 2016-06-22 詹森生物科技公司 Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
CN105008518B (en) 2012-12-31 2020-08-07 詹森生物科技公司 Culturing human embryonic stem cells at an air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10241108B2 (en) 2013-02-01 2019-03-26 Ares Trading S.A. Abnormal syngamy phenotypes observed with time lapse imaging for early identification of embryos with lower development potential
JP6495658B2 (en) 2013-02-08 2019-04-03 国立大学法人京都大学 Method for producing megakaryocytes and platelets
WO2014127289A1 (en) 2013-02-15 2014-08-21 International Stem Cell Corporation Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
CA2901747A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP2966163B1 (en) 2013-03-06 2018-01-17 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
JP2016520291A (en) 2013-03-14 2016-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Production of medial ganglion progenitor cells in vitro
EP3736343A1 (en) 2013-03-15 2020-11-11 Whitehead Institute For Biomedical Research Cellular discovery platform for neurodegenerative diseases
JP6473077B2 (en) 2013-03-21 2019-02-20 国立大学法人京都大学 Pluripotent stem cells for inducing neural differentiation
WO2014157257A1 (en) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 Cell sorting method
WO2014165663A1 (en) 2013-04-03 2014-10-09 Cellular Dynamics International, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
KR102393715B1 (en) 2013-04-05 2022-05-02 유니버시티 헬스 네트워크 Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
WO2014168585A1 (en) 2013-04-10 2014-10-16 Agency For Science, Technology And Research Polycaprolactone microcarriers for stem cell culture and fabrication thereof
CN105338989B (en) 2013-04-12 2022-04-08 赛维里奥·拉弗朗切西卡 Improvements in organs for transplantation
US10961508B2 (en) 2013-04-12 2021-03-30 Kyoto University Method for inducing alveolar epithelial progenitor cells
WO2014174470A1 (en) 2013-04-23 2014-10-30 Yeda Research And Development Co. Ltd. Isolated naive pluripotent stem cells and methods of generating same
DK2992088T3 (en) 2013-04-30 2019-11-11 Univ Leuven Kath CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
US9758763B2 (en) 2013-05-29 2017-09-12 The Regents Of The University Of California Methods and compositions for somatic cell proliferation and viability
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
WO2014200905A2 (en) 2013-06-10 2014-12-18 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
EP3008169B1 (en) 2013-06-10 2021-11-10 Academisch Ziekenhuis Leiden Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures
RU2692595C2 (en) 2013-06-11 2019-06-25 Президент Энд Феллоус Оф Гарвард Колледж SC-β CELLS AND COMPOSITIONS AND METHODS FOR THEIR CREATION
EP3020803B1 (en) 2013-06-11 2020-03-11 Kyoto University Method for producing renal precursor cells
JP6493881B2 (en) 2013-06-12 2019-04-03 国立大学法人京都大学 Method for selecting induced pluripotent stem cells and method for inducing differentiation into blood cells
US9624471B2 (en) 2013-06-12 2017-04-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
AU2014300400B2 (en) 2013-06-28 2019-11-28 Otsuka Pharmaceutical Factory,Inc. Trehalose and dextran-containing solution for transplanting mammalian cells
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
KR102473199B1 (en) 2013-08-16 2022-12-01 예일 유니버시티 Epithelial cell differentiation of human mesenchymal stromal cells
CA2921948C (en) 2013-09-04 2019-11-19 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
WO2015034012A1 (en) 2013-09-05 2015-03-12 国立大学法人京都大学 New method for inducing dopamine-producing neural precursor cells
CA2921081A1 (en) 2013-09-13 2015-03-19 University Health Network Methods and compositions for generating epicardium cells
JP6474795B2 (en) 2013-10-01 2019-02-27 カディマステム リミテッド Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and treatment of amyotrophic lateral sclerosis (ALS)
WO2015064754A1 (en) 2013-11-01 2015-05-07 国立大学法人京都大学 Novel chondrocyte induction method
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US10633625B2 (en) 2013-11-16 2020-04-28 Terumo Bct, Inc. Expanding cells in a bioreactor
US20160298096A1 (en) 2013-11-18 2016-10-13 Crispr Therapeutics Ag Crispr-cas system materials and methods
JP2017504311A (en) 2013-12-11 2017-02-09 ファイザー・リミテッドPfizer Limited Method for generating retinal pigment epithelial cells
WO2015089277A1 (en) 2013-12-12 2015-06-18 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
EP2896688A1 (en) 2014-01-20 2015-07-22 Centre National de la Recherche Scientifique (CNRS) A method of producing beta pancreatic cells from progenitor cells through the use of hydrogen peroxide
WO2015112839A1 (en) 2014-01-23 2015-07-30 President And Fellows Of Harvard College Engineered polymeric valves, tubular structures, and sheets and uses thereof
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
WO2015119642A1 (en) 2014-02-10 2015-08-13 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR102340553B1 (en) 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 Improved reprogramming methods and cell culture platforms
EP3119879B1 (en) 2014-03-19 2019-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for inducing human cholangiocyte differentiation
BR112016021395A8 (en) 2014-03-19 2021-07-13 Vcell Therapeutics Inc methods of generating a pluripotent cell and preparing a test cell or tissue, using a pluripotent cell, and composition
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
WO2015143350A1 (en) 2014-03-20 2015-09-24 Auxogyn, Inc. Quantitative measurement of human blastocyst and morula morphology developmental kinetics
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP3954759A1 (en) 2014-05-16 2022-02-16 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US20170095512A1 (en) 2014-06-02 2017-04-06 Kadimastem Ltd. Methods of inducing myelination and maturation of oligodendrocytes
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
TWI719939B (en) 2014-07-14 2021-03-01 日商中外製藥股份有限公司 Method of identifying protein epitopes
CN108064274A (en) 2014-07-30 2018-05-22 耶达研究及发展有限公司 For cultivating the culture medium of multipotential stem cell
WO2016025510A1 (en) 2014-08-12 2016-02-18 Rappolee Daniel A Systems and methods to detect stem cell stress and uses thereof
EP3183337B1 (en) 2014-08-22 2019-02-06 Procella Therapeutics AB Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
EP3188763B1 (en) 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification
US11261453B2 (en) 2014-09-12 2022-03-01 Whitehead Institute For Biomedical Research Cells expressing apolipoprotein E and uses thereof
KR102617137B1 (en) 2014-09-15 2023-12-27 칠드런'즈 메디컬 센터 코포레이션 Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
US9371516B2 (en) 2014-09-19 2016-06-21 Regenerative Medical Solutions, Inc. Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells
EP3207122B1 (en) 2014-10-14 2019-05-08 FUJIFILM Cellular Dynamics, Inc. Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
KR102100021B1 (en) 2014-10-20 2020-04-13 뉴럴스템, 인크. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
WO2016063986A1 (en) 2014-10-24 2016-04-28 大日本住友製薬株式会社 Production method for retinal tissue
EP3220945A2 (en) 2014-11-17 2017-09-27 Yeda Research and Development Co., Ltd. Methods of treating diseases related to mitochondrial function
GB2548740A (en) 2014-11-25 2017-09-27 Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
WO2016100035A1 (en) 2014-12-19 2016-06-23 Janssen Biotech, Inc. Suspension culturing of pluripotent stem cells
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
EP3240890B1 (en) 2014-12-30 2021-06-16 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
WO2016118824A1 (en) 2015-01-22 2016-07-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
JP7199809B2 (en) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and its administration method
CA2976283C (en) 2015-02-17 2022-04-26 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
SI3059307T2 (en) 2015-02-20 2022-08-31 Inserm(Institut National De La Sante Et De La Recherche Medicale) Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
JP6738572B2 (en) 2015-03-06 2020-08-12 国立大学法人京都大学 Method for inducing differentiation of alveolar epithelial cells
CN107530379A (en) 2015-03-11 2018-01-02 佩特尼资源有限公司 For treating the pancreatic endocrine progenitor cell therapy of obesity and diabetes B (T2D)
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
EP3327118B1 (en) 2015-07-17 2021-12-29 Kyoto University Method for inducing vascular endothelial cells
EP3328995B1 (en) 2015-07-29 2021-03-31 Hadasit Medical Research Services And Development Large scale production of retinal pigment epithelial cells
CA2993912A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EP3331995A1 (en) 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
US11312940B2 (en) 2015-08-31 2022-04-26 University Of Louisville Research Foundation, Inc. Progenitor cells and methods for preparing and using the same
WO2017044488A1 (en) 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
WO2017044483A1 (en) 2015-09-08 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US11649432B2 (en) 2015-09-08 2023-05-16 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
ES2897974T3 (en) 2015-09-11 2022-03-03 Astellas Pharma Inc Method for producing kidney progenitor cells
CA2998287A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
JP6800987B2 (en) 2015-10-19 2020-12-16 フジフィルム セルラー ダイナミクス,インコーポレイテッド Production of virus-accepting pluripotent stem cell (PSC) -derived hepatocytes
AU2016342179B2 (en) 2015-10-20 2022-08-18 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
JP6987769B2 (en) 2015-10-26 2022-01-05 セル キュア ニューロサイエンシズ リミテッド Preparation method of retinal pigment epithelial cells
IL258899B2 (en) 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
SG11201804117XA (en) 2015-11-18 2018-06-28 Univ Georgia Neural cell extracellular vessicles
CN108779435B (en) 2015-12-07 2022-05-03 再生疗法有限公司 Method for the re-derivation of different pluripotent stem cell-derived brown adipocytes
WO2017117333A1 (en) 2015-12-30 2017-07-06 Cellular Dynamics International, Inc. Microtissue formation using stem cell-derived human hepatocytes
WO2017172086A1 (en) 2016-02-19 2017-10-05 Leung Chuen Yan Genetic markers for engraftment of human cardiac ventricular progenitor cells
EP3423158B1 (en) 2016-02-24 2023-11-15 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
WO2017152073A1 (en) 2016-03-04 2017-09-08 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US20210155895A1 (en) 2016-04-04 2021-05-27 Lineage Cell Therapeutics, Inc. Pluripotent Stem Cell-Derived 3D Retinal Tissue and Uses Thereof
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
SG11201809279YA (en) 2016-04-22 2018-11-29 Univ Kyoto Method for producing dopamine-producing neural precursor cells
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
CA3025057A1 (en) 2016-05-25 2017-11-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cancers
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
WO2017216771A2 (en) 2016-06-17 2017-12-21 Genesis Technologies Limited Crispr-cas system, materials and methods
MA45502A (en) 2016-06-21 2019-04-24 Janssen Biotech Inc GENERATION OF FUNCTIONAL BETA CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS WITH GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE
EP3478824A1 (en) 2016-07-01 2019-05-08 Centre National de la Recherche Scientifique - CNRS Amplifying beta cell differentiation with small molecules bet (bromodomain and extraterminal family of bromodomain-containing proteins) inhibitors
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
ES2901379T3 (en) 2016-08-16 2022-03-22 Fujifilm Cellular Dynamics Inc Methods to differentiate pluripotent cells
CN116115629A (en) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 Nucleic acid products and methods of administration thereof
JP7248571B2 (en) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス,インコーポレイテッド Generation of mature lineages from MeCP2-disrupted induced pluripotent stem cells
JP2019533703A (en) 2016-11-02 2019-11-21 エーエーエル サイエンティフィックス,インコーポレイテッド Non-mesenchymal human lung stem cells and methods for their use to treat respiratory diseases
JP7006943B2 (en) 2016-11-04 2022-01-24 国立大学法人 東京大学 Mesenchymal cells and mesenchymal stem cells cryopreservation solution, frozen product, and cryopreservation method
JP7088564B2 (en) 2016-11-10 2022-06-21 ヴィアサイト,インコーポレイテッド PDX1 pancreatic endoderm cells and methods thereof in a cell delivery device
CN109996873A (en) 2016-11-25 2019-07-09 国立研究开发法人理化学研究所 Transplanting cell mass and its manufacturing method
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
AU2017377309B9 (en) 2016-12-14 2021-06-03 Otsuka Pharmaceutical Factory, Inc. Mammalian cell cryopreservation liquid
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
WO2018164240A1 (en) 2017-03-08 2018-09-13 大日本住友製薬株式会社 Method for producing retinal pigment epithelial cells
JP2020511539A (en) 2017-03-16 2020-04-16 リネージ セル セラピューティクス インコーポレイテッド Method to measure the therapeutic effect of retinal disease treatment
EP3601530A1 (en) 2017-03-20 2020-02-05 IFOM Fondazione Istituto Firc di Oncologia Molecolare Method of generating 2 cell-like stem cells
EP3612557B1 (en) 2017-04-18 2022-01-19 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
AU2018255975A1 (en) 2017-04-20 2019-08-15 Oregon Health & Science University Human gene correction
WO2018235583A1 (en) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 Method for predicting differentiation ability of pluripotent stem cell, and reagent for same
KR20200029479A (en) 2017-07-20 2020-03-18 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 Methods of preservation of nerve tissue
CN110945119A (en) 2017-07-20 2020-03-31 国立研究开发法人理化学研究所 Method for maturation of retinal tissue comprising continuous epithelium
AU2018308976A1 (en) 2017-07-31 2020-02-20 Biotime, Inc. Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury
EP3663393A1 (en) 2017-08-23 2020-06-10 Procella Therapeutics AB Use of neuropilin-1 (nrp1) as a cell surface marker for isolating human cardiac ventricular progenitor cells
SG11202001889YA (en) 2017-09-08 2020-03-30 Riken Cell aggregate including retinal tissue and production method therefor
WO2019054514A1 (en) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 Method for producing retinal tissues
EP3683304A4 (en) 2017-09-14 2021-06-09 Riken Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter
US20210363521A1 (en) 2017-11-09 2021-11-25 Vertex Pharmaceuticals Incorporated CRISPR/CAS Systems For Treatment of DMD
US11618884B2 (en) 2017-11-14 2023-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
US11679148B2 (en) 2017-11-24 2023-06-20 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for treating cancers
KR20200088880A (en) 2017-11-24 2020-07-23 스미또모 가가꾸 가부시끼가이샤 A method for producing a cell mass comprising nerve cells/tissue and non-nerve epithelial tissue, and a cell mass therefrom
AU2018373588A1 (en) 2017-11-24 2020-07-02 Sumitomo Chemical Company, Limited Method for producing cell mass including pituitary tissue, and cell mass thereof
EP3724332A1 (en) 2017-12-14 2020-10-21 CRISPR Therapeutics AG Novel rna-programmable endonuclease systems and their use in genome editing and other applications
EP4000568A1 (en) 2017-12-29 2022-05-25 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
EP3757208A4 (en) 2018-02-19 2021-12-01 Sumitomo Dainippon Pharma Co., Ltd. Cell aggregate, mixture of cell aggregates, and method for preparing same
US20210054353A1 (en) 2018-03-19 2021-02-25 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
CA3095717A1 (en) 2018-03-30 2019-10-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20210009956A1 (en) 2018-03-30 2021-01-14 Kyoto University Cardiomyocyte maturation promoter
AU2019256723A1 (en) 2018-04-20 2020-11-05 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
EP3572512A1 (en) 2018-05-24 2019-11-27 B.R.A.I.N. Ag A method for engineering a protein
WO2020006273A1 (en) 2018-06-27 2020-01-02 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University Plate-shaped cartilage derived from pluripotent stem cells and method for producing plate-shaped cartilage
EP3828262A4 (en) 2018-07-23 2022-03-30 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
EP3833383A1 (en) 2018-08-06 2021-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
CA3110464A1 (en) 2018-08-24 2020-02-27 Sumitomo Chemical Company, Limited Cell cluster including olfactory neuron or precursor cell thereof, and method for producing same
SG11202102876XA (en) 2018-09-28 2021-04-29 Otsuka Pharma Factory Inc Mammal cell preserving solution containing acarbose or stachyose
JP7437766B2 (en) 2018-10-31 2024-02-26 国立大学法人京都大学 Method for producing pluripotent stem cells that are free from mesendoderm differentiation resistance
JP7410518B2 (en) 2018-11-15 2024-01-10 Jsr株式会社 Method for producing brain organoids
JP2022513073A (en) 2018-11-19 2022-02-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Biodegradable tissue replacement implants and their use
WO2020113025A1 (en) 2018-11-28 2020-06-04 Milica Radisic Methods for tissue generation
JP7446242B2 (en) 2018-12-20 2024-03-08 住友化学株式会社 Cell population containing embryonic erythroblasts and its production method, cell culture composition, and compound testing method
WO2020130147A1 (en) 2018-12-21 2020-06-25 国立大学法人京都大学 Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020138430A1 (en) 2018-12-28 2020-07-02 国立研究開発法人理化学研究所 Therapeutic drug for disease accompanied by disorders in retinal system cells or retinal tissue
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
US20220104481A1 (en) 2019-02-13 2022-04-07 Tigenix, S.A.U. Cryopreservation of stem cells
CA3127851A1 (en) 2019-02-27 2020-09-03 Tigenix, S.A.U. Improved stem cell populations for allogeneic therapy
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2020209959A1 (en) 2019-03-08 2020-10-15 Crispr Therapeutics Ag Nucleobase-editing fusion protein systems, compositions, and uses thereof
US20220145274A1 (en) 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
CN113557311A (en) 2019-03-13 2021-10-26 大日本住友制药株式会社 Quality evaluation method for neural retina for transplantation and neural retina sheet for transplantation
KR20210144793A (en) 2019-03-29 2021-11-30 고리츠다이가쿠호진 요코하마시리츠다이가쿠 Screening Methods and Toxicity Assessment Methods
US20220192178A1 (en) 2019-04-26 2022-06-23 Otsuka Pharmaceutical Factory, Inc. Trehalose-containing liquid for mammalian cell preservation
JPWO2020218480A1 (en) 2019-04-26 2020-10-29
WO2020225606A1 (en) 2019-05-08 2020-11-12 Crispr Therapeutics Ag Crispr/cas all-in-two vector systems for treatment of dmd
JP2022534555A (en) 2019-05-09 2022-08-02 フジフィルム セルラー ダイナミクス,インコーポレイテッド Method for producing hepatocyte
US20220259561A1 (en) 2019-05-14 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
EP3973049A1 (en) 2019-05-22 2022-03-30 Hadasit Medical Research Services and Development Ltd. Methods of culturing human pluripotent cells
EP3754014A1 (en) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automated method for preparing retinal pigment epithelium cells
WO2020264072A1 (en) 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
JP7385244B2 (en) 2019-06-27 2023-11-22 国立大学法人 東京大学 Method for isolating pancreatic progenitor cells
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
WO2021030424A1 (en) 2019-08-13 2021-02-18 Semma Therapeutics, Inc. Pancreatic differentiation
JPWO2021045217A1 (en) 2019-09-06 2021-03-11
WO2021069593A1 (en) 2019-10-09 2021-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) T cells modified to express mutated cxcr4 or partially deleted and uses thereof
CN115175989A (en) 2019-11-20 2022-10-11 住友制药株式会社 Method for freezing nerve cells
CN115003156A (en) 2019-11-20 2022-09-02 住友制药株式会社 Method for freezing cell aggregates
KR20220106975A (en) 2019-11-25 2022-08-01 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T-Cell Master Cell Bank
WO2021105407A1 (en) 2019-11-29 2021-06-03 Novadip Biosciences miRNA-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND THE TREATMENT OF TISSUE DISORDERS
TW202136500A (en) 2019-11-29 2021-10-01 比利時商諾瓦迪生物科學公司 Biomaterials for the prevention and the treatment of tissue disorders
WO2021117886A1 (en) 2019-12-12 2021-06-17 国立大学法人千葉大学 Freeze-dried preparation containing megakaryocytes and platelets
EP3875581A1 (en) 2020-03-02 2021-09-08 Centre d'Etude des Cellules Souches (CECS) Automated method for preparing keratinocytes
EP3875580A1 (en) 2020-03-02 2021-09-08 Centre d'Etude des Cellules Souches (CECS) Methods for preparing keratinocytes
CN115605581A (en) 2020-03-13 2023-01-13 戈利弗疗法公司(Fr) Liver stem cell-like cells for the treatment and/or prevention of fulminant liver diseases
BR112022018640A2 (en) 2020-03-19 2022-11-08 Orizuru Therapeutics Inc METHODS FOR PRODUCING A CELL POPULATION COMPRISING CARDIOMYOCYTES AND FOR PURIFYING CARDIOMYOCYTES, CELL POPULATION CONTAINING CARDIOMYOCYTES, AND, AGENT FOR CELL TRANSPLANTATION THERAPY
US20230212519A1 (en) 2020-03-19 2023-07-06 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
EP4132479A1 (en) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
MX2022015012A (en) 2020-05-29 2023-03-03 Fujifilm Cellular Dynamics Inc Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof.
BR112022024064A2 (en) 2020-05-29 2023-01-31 Fujifilm Cellular Dynamics Inc RETINAL PIGMENTED EPITHELIUM BILAYER AND PHOTORECEPTORS AND USE THEREOF
US20230235319A1 (en) 2020-06-12 2023-07-27 Bayer Aktiengesellschaft Crispr-cas12a directed random mutagenesis agents and methods
WO2022014604A1 (en) 2020-07-13 2022-01-20 国立大学法人京都大学 Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
JPWO2022054925A1 (en) 2020-09-11 2022-03-17
EP4201428A1 (en) 2020-09-11 2023-06-28 Sumitomo Pharma Co., Ltd. Medium for tissue for transplantation
WO2022063224A1 (en) 2020-09-24 2022-03-31 中国科学院动物研究所 Activated pluripotent stem cell, and preparation method therefor and use thereof
US20230399622A1 (en) 2020-10-16 2023-12-14 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
EP4005577A1 (en) 2020-11-26 2022-06-01 Novadip Biosciences Cellular and/or extracellular extracts for preventing and/or treating cancer and/or inflammation
CN112538458A (en) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) Method for reprogramming cells
KR20230079442A (en) 2020-12-23 2023-06-07 미쓰이 가가쿠 가부시키가이샤 Culture member and use thereof
JPWO2022191216A1 (en) 2021-03-09 2022-09-15
WO2022207889A1 (en) 2021-04-01 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Liver organoid manufacturing methods, liver organoids obtained with the same, and uses thereof
EP4319876A1 (en) 2021-04-07 2024-02-14 Fujifilm Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
AU2022258097A1 (en) 2021-04-11 2023-11-02 President And Fellows Of Harvard College Cardiomyocytes and compositions and methods for producing the same
KR20240005837A (en) 2021-05-03 2024-01-12 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Method for generating mature corneal endothelial cells
KR20240005887A (en) 2021-05-07 2024-01-12 아스텔라스 인스티튜트 포 리제너러티브 메디슨 How to Generate Mature Hepatocytes
AU2022280062A1 (en) 2021-05-28 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
AU2022282379A1 (en) 2021-05-28 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
WO2022258511A1 (en) 2021-06-07 2022-12-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for generating highly functional hepatocytes by differentiating hepatoblasts
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
KR20240021218A (en) 2021-06-11 2024-02-16 바이엘 악티엔게젤샤프트 Novel type V RNA programmable endonuclease system
IL309344A (en) 2021-06-17 2024-02-01 Univ Kyoto Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
WO2023009676A1 (en) 2021-07-28 2023-02-02 Lineage Cell Therapeutics, Inc. Expansion of retinal pigment epithelium cells
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023039588A1 (en) 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
WO2023049826A1 (en) 2021-09-23 2023-03-30 President And Fellows Of Harvard College Genetically encoded voltage indicators and uses thereof
WO2023069979A1 (en) 2021-10-20 2023-04-27 University Of Rochester Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
US20230226116A1 (en) 2021-10-20 2023-07-20 University Of Rochester Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se
WO2023070019A1 (en) 2021-10-21 2023-04-27 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023077140A2 (en) 2021-11-01 2023-05-04 Vertex Pharmaceuticals Incorporated Stem cell derived pancreatic islet differentiation
WO2023095149A1 (en) 2021-11-29 2023-06-01 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating spinal cord injury
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023167986A1 (en) 2022-03-02 2023-09-07 Lineage Cell Therapeutics, Inc. Methods and compositions for treating hearing loss
WO2023178239A1 (en) 2022-03-16 2023-09-21 The Children's Medical Center Corporation Hpsc-derived articular chondrocyte compositions, systems and methods of use thereof
WO2023199113A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2023230391A1 (en) 2022-05-26 2023-11-30 Tender Food, Inc. Plant-based shredded meat products, and methods of producing the same
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
US20240090531A1 (en) 2022-09-16 2024-03-21 Tender Food, Inc. Plant and animal cell blended meat products and methods of producing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060078A (en) * 1960-12-02 1962-10-23 Burlington Industries Inc Bonding of polyethylene terephthalate fibers to certain rubbers
GB1051340A (en) * 1962-09-21 1900-01-01
JP2740320B2 (en) 1988-08-04 1998-04-15 アムラド・コーポレイション・リミテッド In vitro propagation of embryonic stem cells
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
JP2750464B2 (en) * 1990-01-30 1998-05-13 日本ゼオン株式会社 Method for producing fiber-rubber composite
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
WO1994003585A1 (en) * 1992-08-04 1994-02-17 Commonwealth Scientific And Industrial Research Organisation A method for maintaining embryonic stem cells and avian factor useful for same
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) * 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5449620A (en) * 1994-01-25 1995-09-12 Thomas Jefferson University Apparatus and method for culturing embryonic stem cells
US5541081A (en) * 1994-03-22 1996-07-30 President And Fellows Of Harvard College Process for assessing oocyte and embryo quality
JP3496292B2 (en) * 1994-09-30 2004-02-09 日本ゼオン株式会社 Composites of nitrile group-containing highly saturated copolymer rubber and fiber
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5654099A (en) * 1996-02-21 1997-08-05 Dayco Products, Inc. Method of improving adhesion between alkylated chlorosulfonated polyethylene (ACSM) or chlorosulfonated polyethylene (CSM), and resorcinol formaldehyde latex (RFL) treated polyester cord
IL154159A0 (en) * 2000-08-01 2003-07-31 Yissum Res Dev Co Directed differentiation of ebryonic cells
US20070077654A1 (en) * 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells

Also Published As

Publication number Publication date
EP1640448A3 (en) 2006-04-26
US20090011503A1 (en) 2009-01-08
CA2190528A1 (en) 1996-07-25
US8273569B2 (en) 2012-09-25
US20110256623A1 (en) 2011-10-20
US6200806B1 (en) 2001-03-13
AU4758496A (en) 1996-08-07
US7029913B2 (en) 2006-04-18
US7781216B2 (en) 2010-08-24
US20010024825A1 (en) 2001-09-27
US20030008392A1 (en) 2003-01-09
US20060040383A1 (en) 2006-02-23
US5843780A (en) 1998-12-01
EP0770125A4 (en) 1998-01-14
US20150056698A1 (en) 2015-02-26
WO1996022362A1 (en) 1996-07-25
US20120328582A1 (en) 2012-12-27
EP0770125A1 (en) 1997-05-02
EP1640448A2 (en) 2006-03-29
US20050158854A1 (en) 2005-07-21
US20050164381A1 (en) 2005-07-28
US7582479B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CA2190528C (en) Primate embryonic stem cells
Martin Teratocarcinomas as a model system for the study of embryogenesis and neoplasia
AU2016324669B2 (en) Culture method for differentiating primordial germ cells into functionally mature oocytes
Thomson et al. Isolation of a primate embryonic stem cell line.
CA2456981C (en) Alternative compositions and methods for the culture of stem cells
EP2453010A1 (en) Neural progenitor cells derived from embryonic stem cells
Suemori et al. Establishment of the Embryo‐derived Stem (ES) Cell Lines from Mouse Blastocysts: Effects of the Feeder Cell Layer.
KR101538089B1 (en) embryonic stem cell-like cells
Andrews et al. Embryonal carcinoma cells as embryonic stem cells
AU2003269457A1 (en) Human foreskin cells suitable for culturing stem cells
US20070298496A1 (en) Method of deriving pluripotent stem cells from a single blastomere
US20030073234A1 (en) Clonal human embryonic stem cell lines and methods of generating same
JP2007516720A (en) Embryonic stem cell line and method for producing the same
Fan et al. A modified culture medium increases blastocyst formation and the efficiency of human embryonic stem cell derivation from poor-quality embryos
Pall et al. Establishment of an embryonic stem cell line from blastocyst stage mouse embryos
CN116103227B (en) Construction method of novel mouse trophoblast stem cells
TWI392736B (en) Method of deriving pluripotent stem cells from a single blastomere
Amit et al. Isolation and maintenance of primate ES cells
Vrana et al. Colloquium Nonhuman primate parthenogenetic stem cells
Davies et al. Embryonic stem cells and the capture of pluripotency
JPH08116966A (en) Bovine embryonic stem cell and its preparation
Draper et al. Human embryonal
US20090305404A1 (en) Methods and compositions relating to blastomere-derived human embryonic stem cells
Candan et al. Derivation and Characterization of New hESC Lines from Supernumerary Embryos, Experience from Turkey

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160119